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ABSTRACT 
 
C10 Semi-Peptoid β-turn Peptidomimetics: Syntheses, Characterization and Biological 
Studies. 
(May 2006) 
Ernest Nnanabu, B.S., Linfield College 
Chair of Advisory Committee: Dr. Kevin Burgess 
 Over the years, the Burgess group has been focusing on the preparation and 
testing of small molecules that mimic protein secondary structures for protein-protein 
interactions.   The most successful compounds made are C10 peptide macrocycles that 
effectively mimic β-turns and have given promising results from biological testing. These 
peptide macrocycles have also been dimerized to give even more effective ligands for 
protein-protein interaction.  
 The successes of the peptide macrocycles have enabled us to look into increasing 
the chemical diversity of our libraries. This we believe will not only improve our ability 
to obtain high affinity ligands for the receptors of interest, but will also allow us to 
investigate other receptors.    To achieve this, peptoids were incorporated into the C10 
system to replace the peptides in the i+1 and i+2 positions.  With the help of Microwave 
irradiation, semi-peptoid macrocycles were synthesized with a total reaction time of less 
than 2 h.  These compounds were characterized and found to mimic β-turn, and show 
promising biological activity towards the Insulin-like growth factor 1 receptor (IGF-IR). 
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CHAPTER I 
INTRODUCTION 
 
1.1 Peptidomimetics and Protein-Protein Interactions 
At the core of life are protein-protein interactions.  Many physiological processes 
require protein associations or dissociations to take place.  Cellular activities such as cell 
division, information transfer (signal transduction), cell growth and death, cell-cell 
recognition, and cellular defense require very precise and careful scripting of protein 
associations.1,2  A lot of successful work has been done in elucidating the binding sites 
(hot spots) via X-ray crystallography and genetic mutations.2-4  Although protein-protein 
interactions have been identified as a key area of study in medicinal chemistry, the 
identification of small molecules that bind favorably to protein hot spots compared to 
natural ligands has been difficult.5  Interest in generating small molecules that can bind to 
proteins and affect their functions is enormous because  developing these compounds will 
help in finding cures to a lot of diseases that affect humans today.    
Unlike natural proteins and peptides, which are usually large molecules, 
expensive, and very difficult to get into the cell, small molecules can be cheaper and easy 
to work with.  Most of the early work done on mimicry of ligands that bind to receptor 
proteins focused mainly on the side chains similarities of the binding sites to the small 
molecules.6   The major issue why small molecules do not compete favorably with natural 
ligands is surface area.7  The binding sites for protein-protein interactions have large 
surface area of about 600 Å2.8  This allows the proteins to reduce problems caused by 
solvation, which most of the early work on small molecule peptidomimetics neglected.8   
 
 
 
_________ 
This thesis follows the style of the Journal of Organic Chemistry. 
 
 
 -  - 
 
2 
 
Now the question is how can chemists overcome solvation problems without 
resorting to large molecules that will be very difficult to get into the cell?  Goodsell and 
co-workers8 found out that most of the protein-protein/peptide interactions involve a 
hydrophobic core surrounded by a hydrophilic periphery.  The hydrophobic center helps 
the interactions by eliminating the water that solvates the protein and, therefore bringing  
 interacting molecules close together.  Based on these observations, molecules with a 
hydrophobic core and hydrophilic sides were designed.  To increase the surface area of 
the system, many hydrophilic small molecule mimics of peptide side chains were built on 
a hydrophobic scaffold. 
   
1.2 Tumor Necrosis Factor-α  (TNFα) and Receptors  
The TNF ligand family are pleiotropic cytokines produced mostly by activated 
macrophages and lymphocytes.9,10  They are made up of 18 genes encoding 19 type II 
transmembrane proteins, with a conserved trimeric C-terminal domain called the TNF 
homology domain (THD), which is responsible for receptor binding and has a sequence 
identity between family members of 20-30 %.9,11,12.  Type II transmembrane proteins are 
proteins with an intracellular N-terminus and extracellular C-terminus.  Although the 
ligands are formed as membrane proteins, for cell-cell contact transfer of signaling 
information between neighboring cells, they have to be cleaved and solubilized to 
become active cytokines (Figure 1.1).11   Proteases are involved in these cleaves are 
ligand specific. Metalloproteases of the ADAM (a disintegrin and metalloproteinase 
domain) family act on TNF ligands.9,11  Other members of this superfamily include 4-
1BB ligand, APRIL, CD 27, CD 30, CD 40, FAS ligand, LT-α (TNF B), LT-β (TNF C) 
etc.   
TNF, in addition to causing necrotic cell death, may also cause apoptotic cell 
death, cellular proliferation, differentiation, inflammation, tumorigenesis and viral 
replication.11  Though the primary role of the ligand is immune regulation, they are also 
known to be heavily involved in pathological disorders like rheumatoid arthritis, asthma, 
septic shock, irritable bowel disorder, heamorrhagic fever, and cachexia.11,13  Most of the 
works on TNF have focused on disrupting steps in the TNF pathway.11,14  Inhibitors of the 
 -  - 
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actions or production of TNFα includes some monoclonal antibodies, penteoxifylline, 
p65 antisense, oligonucleotides, and metalloproteinase inhibitors.  Some protein therapies 
based on soluble recombinant TNF receptor and anti-TNF, humanized monoclonal 
antibodies, have been approved by the FDA.  The recombinant TNF receptor (Etanercept 
or Enbrel) and the monoclonal antibody (Infliximab or Remicade) are now being used to 
treat rheumatoid arthritis and Crohn’s disease respectively.  These therapies are very 
expensive because of the fact that large proteins are used, hence the need for 
development of small molecule-based drugs.  Figure 1.1 shows an overview of the 
activation (trimerization) and binding of both the ligands and receptors of the TNF 
superfamily.  These will be discussed in detail in later sections. 
 
 
TRAF
trimerize
activity
soluble
shedReceptor
Ligand
trimer
trimer
activity
 
Figure 1.1.  TNF superfamily ligand-receptor interactions. 
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1.2.1 Structure of TNFα  
TNF ligand  (also called TNF-α, cachectin, differentiation inducing factor DIF, 
and TNFSF2) is a 26 kDa transmembrane protein.14  It is cleaved by the metalloprotease 
TNFα-converting enzyme (TACE) into a 17 kDa soluble TNF form.11  The THD is a 150 
amino acid sequence with a conserved framework of aromatic and hydrophobic residues.   
The THDs of the superfamily share a virtually identical tertiary fold and associate 
to form trimeric proteins.15  They are β-sandwiched structures with two stacked β-pleated 
sheets which are formed by 5 anti-parallel β-strands that adopt a classical ‘jelly-roll’ 
topology.16,17  The THD trimers (Figure 1.2) are bell shaped truncated pyramids about 60 
Å high, with variable loops coming out of the conserved anti-parallel β-strands.9  The 
arrangement of the inner sheets allow for a maximum Vander Waals interaction between 
the monomers.9  TNF contains a single disulfide bridge that links the CD and EF loops 
(Figure  1.2). 11,13 
 
 
Figure 1.2. Human Tumor Necrosis Factor-α (TNFα)*  
 
 
________ 
*Reprinted with permission from “The molecular architecture of the TNF superfamily”  Bodmer, J. L.; Schneider, P.; 
Tschopp, J. TRENDS in Biochem. Sci. 2002, 27, 19-26. © 2002 Elsevier Science Ltd. 
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1.2.2 TNF Receptors  
The TNF receptors are members of a superfamily of about 29 proteins that are 
activated by one or more ligands.9  They are characterized by extracellular domains of 
repeated cysteine- rich domains (CRDs) (Figure 1.3) which are involved in binding to the 
ligands.  Most of the TNF receptors are type I (extracellular N-terminus and intracellular 
C -terminus) transmembrane proteins.  Soluble receptors can also be generated by 
proteolytic activity9 or the alternative splitting of the exon encoding the transmembrane 
domain.9,11,18  The soluble receptor  are important in modulating the activities of their 
cognate ligands such as interaction of with TNF that interfere with the inflammatory 
responses.11,19,20   
Some TNF receptor family binds to non-TNF  ligands.  For instance both NGFR 
and P75 bind with low affinity to neurotrophins.9,21,22  TNFα  binds  to two receptors (in 
the receptor family); the TNF  Receptor 1 ( TNFR1), and the TNF Receptor 2 (TNFR2).*  
Both TNFR1 and TNFR2 contain an extracellular  pre-ligand binding assembly domain 
(PLAD) which is distinct from the ligand binding region. The PLAD pre-complexes the 
receptors and helps trimerization particularly upon activation by TNF.11  TNFR1 contains 
a death domain (DD)  motif of about 80 amino acids that induces cell death.11  The DD 
interacts with a number of proteins that primarily signal cell death.  These proteins are 
prevented from binding to the death domain by the silencer of the death domain protein 
(SODD).11  The binding of the TNF-α causes a dissociation of the SODD-DD complex 
and allows other proteins to access the DD module.11  TNFR2 does not have the death 
domain motif, it signals for cell death through its cytoplasmic domain by inducing mTNF 
expression which then signals apoptosis via TNFR1.11  TNF-α has a 20-30 times higher 
affinity to TNFR1 than TNFR2.11  The binding  of TNF to TNFR1 also activates  various  
cell activities like inflammation and proliferation via NFκΒ, c-Jun kinase (JNK ), and 
other proteins. 9,11,19-21,23 
 
______ 
*TNFR1 is also called p55, p55TNFR, TNFRSFIA, CD120a, TNF-R55, p60, TNF –R-I, TNFAR, and TNFR-b, while 
TNFR2 is also known as TNFRSF1B, CD 120b, p75, p75TNFR, TNFR-75, p80, TNF-R-II, TNFBR, and TNFR-a. 
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Figure 1.3. Representation of the Cysteine Rich Domains  (CRDs) of TNFR1 that are 
involved in binding to TNFα.* 
 
1.2.3 Hot spots and Interaction of TNF-α  with TNFR1  
TNFα and LTα (TNFβ) are highly homologous proteins which binds to both 
TNFR1 and TNFR2 to induce biological activities.  There is no known crystal structure 
of the TNFα /TNFR1 complex.  The structure of the TNFβ and TNFR1 complex which is 
available (Figure 1.4a), was used to study the binding of TNFα and TNFR1 since TNFα   
and TNFβ  are homologous.24  With some adjustments the interaction of TNFα  and 
TNFR1 was proposed to involve turn regions of the ligand as shown in Table 1.1 and 
Figure 1.5.  This is consistence with results of from site directed mutagenesis 
studies.16,25,26  Figure 1.4b shows the TNF and TNFRI interaction and the critical binding 
site on the receptor.24 
 
 
 
________ 
*Reprinted with permission from “The molecular architecture of the TNF superfamily”  Bodmer, J.-L.; Schneider, P.; 
Tschopp, J. TRENDS in Biochem. Sci. 2002, 27, 19-26. © 2002 Elsevier Science Ltd. 
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A 
          
B        C  
Figure 1.4. (a) Crystal structure of TNFβ/TNFR1 complex. TNFβ in green, TNFR1 in 
blue, and the two interaction surfaces in red and orange.* (b) Structural view of TNFα   
and receptor interactions (an interaction surface in yellow). (c) Loop 1 of domain 3 of the 
TNFR (the critical binding site ). 
 
_______ 
*Reprinted with permission from “The molecular architecture of the TNF superfamily”  Bodmer, J.-L.; Schneider, P.; 
Tschopp, J. TRENDS in Biochem. Sci. 2002, 27, 19-26. © 2002 Elsevier Science Ltd. 
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Table 1.1. Sequences of turn regions in TNFα postulated for binding to TNFR1. 
Loop: residues i i +1 i + 2 i + 3 
     
1:19 –22 Asn Pro Gln Ala 
2: 32 –35  Arg Ala Asn Ala 
3: 85 – 88  Val Ser Tyr Gln 
4: 145 – 148  Ala Glu Ser Gly 
 
 
a loop 1         b. loop 2            c. loop 3         d. loop 4 
 
Figure 1.5. Local conformations of the TNFα β-turn regions 1 – 4. 
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1.2 Neurotrophins and Their Receptors 
Neurotrophins are a family of dimeric proteins that regulate differentiation and 
survival of neurons of the central and peripheral nervous systems.27-29  There are four 
members of this protein family; nerve growth factor (NGF), neurotrophin-3 (NT-3), 
brain-derived neurotrophic factor (BDNF), and neurotrophin-4/5 (NT-4/5), each 
controlling distinct neuronal populations.27-30   These and other biological activities of the 
neurotrophins depend on their interactions with their transmembrane receptors, namely 
tyrosine kinases (Trk) and TNFR2 (p75).  Abnormalities of NGF and other neurotrophins 
are thought to be directly implicated in neurodegenerative diseases such as Alzheimer 
and Parkinson's diseases, and certain types of cancer. 28,31,32  This has led to efforts to 
understand their structures and function to develop therapeutic agents to treat these 
important diseases. 
 Docking of the neurotrophins to their respective receptors induces dimerization 
of these receptors which causes activation of cell signaling processes.27,33     
Neurotrophins bind to Trk selectively with high affinity (Kd ~ 10-11M).34  Figure 1.6 
shows that NGF binds specifically to TrkA,35   while BDNF and NT-4/5 are specific to 
TrkB.36,37  NT-3 interacts with all the Trk receptors but it is more selective forTrkC,33,36  
All neurotrophins  bind to the p75 receptor with lower affinities (Kd ~ 10-9 M) than their 
interactions with Trk receptors.38-40 
 -  - 
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Figure 1.6.  Relationships of neurotrophins and their receptors. 
 
1.3.1 Structure of Neurotrophins  
Neurotrophins are members of the cystine knot superfamily, a group of proteins 
that share a common structural feature of three disulfide bridges.  They are approximately 
25 kDa proteins that exhibit high sequence homology (more than 50 % identical) and 
exist exclusively as dimers.27,28   Each monomer (Figure 1.7) consists of three antiparallel 
pairs of β-strands connected with four β-hairpin loops, with three disulfide bonds 
forming the core of the structure (cystine knot).   Hydrophobic residues along the β-
strands stabilize the dimer form of the proteins.  The residues along the β-strands help in 
maintaining the proteins fold structure.  While highly variable residues in the N-termini, 
C-termini, and turn regions are thought to be involved in receptor binding and 
activation.27,41,42   
 -  - 
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Figure 1.7.  Structure of neurotrophins (a) NGF, (b) NT-3, (c) BDNF, (d) NT-4/5.* 
 
1.3.2 Structure of Neurotrophin Receptors 
The sequences of the Trk family receptors are highly homologous.33   Although 
the complete three-dimensional structure of any Trk receptors is unknown, their 
extracellular domains have been classified into five sub-domains based on sequence 
similarities to other known receptors (Figure 1.8).43  These sub-domains made up of two 
cysteine rich clusters (sub-domain 1 and 3), with leucine-rich motif (sub-domain 2) 
between them, and two immunoglobulin (Ig)-like domains (4 and 5), located close to the 
membrane.33,37,44  The intracellular domain contains a phosphorylation site, which upon 
activation, triggers downstream signaling pathways that mediate neurite outgrowth, 
neuronal differentiation, or survival.45-47   
The p75 receptor (TNFR2) is a member of the tumor necrosis factor (TNF) 
receptor superfamily, which has been discussed in the TNF receptor section.  The exact 
roles of the p75 receptor are not known, but it was shown that this receptor could induce 
various responses depending on the cellular context in which it is expressed.   
 
 
______ 
*Reprinted with permission from “Molecular Basis of Neurotrophin – Receptor Interactions”  Mookda Pattarawarapan 
and Kevin Burgess; Journal of Medicinal Chemistry 2003, 46, 5278. © 2003 American Chemical Society. 
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Binding of neurotrophin to p75 can cause apoptosis in cells that over expressed the 
receptor,48-54  It can also work in cooperation with Trk to mediate Trk activities at low 
neurotrophin concentration in cells that co-express both the receptors.34,38,45,55,56 
 
C1
LRR
C1
Ig1
Ig2
CR1
CR2
CR3
CR4
Extracellular
region
Intracellular
region
Transmembrane domain
Tyrosine
kinase
domain
Death
domain
TrkA, B, C p75
 
 
Figure 1.8.  Schematic representation of neurotrophin receptors; Trk and p75* 
 
1.3.3 Hot Spots and Interaction of NGF and Receptors 
NGF is the most studied neurotrophin.  These studies involve extensive site-
directed mutagenesis experiments, 57-69 and crystal structures  for NGF,70,71 its receptor 
(TrkA-d5)4 and NGF/TrkA-d5 complex.72    The mutagenesis experiments have revealed  
N-terminus  to be the most important region for NGF specificity to TrkA.57,61,63,63,60  The 
C-terminal residues (112-118) are also shown to be essential for receptor activation.57,64 
Mutations of the β-hairpin loops have been shown to affect binding of NGF to TrkA.60  
 
 
______ 
*Reprinted with permission from “Molecular Basis of Neurotrophin – Receptor Interactions”  Mookda Pattarawarapan 
and Kevin Burgess; Journal of Medicinal Chemistry 2003, 46, 5278. © 2003 American Chemical Society. 
 
 -  - 
 
13 
Point mutations studies show that residues 48-49 in loop 2 and 96-98 in loop 4 also 
induce NGF-like activity when substituted into NT-3 skeleton.68,69  Scattered points in the 
β-strand bundles are important for binding to TrkA.59,66  The charged residues located on 
two discontinuous regions of the ligand are important in binding to p75 as shown by 
alanine mutation of three lysine residues (K32, K34 in loop 1 and K95 in loop 4),  loop 3 
(D72, K74, H75) and the C-terminus (111-115).58,64,65,73,74     
Crystallographic analysis of NGF/TrkA-d5 complex supports the results from 
mutagenesis studies that residues in the N-terminus and along the β-sheet regions can 
contribute significantly to the binding of NGF to TrkA.72  The crystal structure reveals 
two ligand-receptor binding interfaces (Figure 1.9a).  The region involving the N-
terminus (residues 2-13) of NGF, adopts a single helix structure upon complexation with 
the hydrophobic pocket on the 'ABED' sheet of TrkA.  This interface was called the 
"specific patch" (Figure 1.9b), which implies that the N-terminus of NGF governs 
specificity for binding to TrkA.39  The other region involving NGF residues along the β-
strand bundle and in loop 1 (30-35) packs against the loops at the C-terminal end of 
TrkA-d5.  This interface was called the "conserved patch" (Figure 1.9c) because residues 
in this region are highly conserved in all the neurotrophins.43   
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(a) 
 
 
 
              
 
Figure 1.9.  NGF/TrkA-d5 complex. (a) The binding epitopes of NGF to TrkA-d5, (b) 
the specific patch, (c) the conserved patch. NGF monomers are in blue and red; TrkA-d5 
is in green.* 
 
 
 
 
______ 
*Reprinted with permission from “Molecular Basis of Neurotrophin – Receptor Interactions” Mookda Pattarawarapan 
and Kevin Burgess; Journal of Medicinal Chemistry 2003, 46, 5278. © 2003 American Chemical Society. 
 
(b)      (c) 
 
 
(b)                                                          (c) 
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1.3.4 Interactions of NT-3 with TrkC and p75 
The crystallographic structure of the complexation of NT-3 and TrkC has not 
been reported, but the crystal structures of NT-3 and the fifth domain of TrkC is known.  
Mutagenesis studies have revealed key structural information concerning the hot spots 
that seem to determine NT-3 affinity to TrkC and p75.62,68,73,75   
Interaction of NT-3 with TrkC seems to be different from the NGF/TrkA binding.  
It was found from replacement experiment, that the N-terminus of NT-3 is not essential 
for binding of NT-3 to TrkC.60  Residues on the central β-strand bundles are shown to 
cause maximum effect on TrkC binding after mutation.73,75Alanine mutation of R103 of 
NT-3 indicates  that R103 is the most important binding determinant for association with 
TrkC.73  Hydrophilic residues along the β-strands (T22, Y51, E54, R56, K80 and Q83) 
were also identified from alanine scanning mutagenesis to be critical for TrkC binding 
affinity and activity.73 Replacing residues in the loop regions of NT-3  with 
corresponding residues  from NGF  does not  sufficiently  affect NT-3 activities.75  But, 
replacing loop  of NGF with corresponding loop of NT-3  induces TrkC activities.68  This 
means that the loop region plays somewhat a role in NT-3 binding to TrkC. 
Just like in NGF, the key recognition elements of NT-3 for binding to the p75 
receptor have also been found via mutagenesis, to be the positively charged residues.74,76   
These residues included R31, H33, Q34 in loop 1 and K73 in loop 4.73,74  Figure 1.10 
shows the critical residues for NT-3 binding to its receptors.76 
 
 -  - 
 
16 
 
Figure 1.10.  Binding epitopes of NT-3 to TrkC (red) and p75 receptor (green).* 
     
1.3.5 Structure Based Design of Functional Mimics of Neurotrophins 
 Neurotrophins, large polypeptides that play important role in regenerating the 
central and peripheral neurons during and after neuronal damages, are very valuable in 
the treatment of neurodegenerative diseases.28,31,32  These hormones are not efficient 
therapeutic agents due to poor bioavailability (ie proteolytic instability and low blood 
brain barrier permeability) .77  Furthermore, they are expensive and can partially bind to 
multiple receptors  thereby causing pleiotrophic effects.  Hence the need for stable 
bioavailable small molecules that can selectively activate or inhibit the activities of the 
Trk receptors. 
Small molecule ligands that can mediate NGF responses (Figure 1.11) have been 
identified via high throughput screening, but none have been reported for the other 
members of neurotrophin family.  These small molecules do not interact directly with  
 
 
_______ 
*Reprinted with  permission from “ Crystal Structure of Neurotrophin-3 Homodimer shows distinct regions are used to 
bind to its Receptors” Butte, M. J.; Hwang, P. K.; Mobley, W. C.; Fletterick, R. J. Biochemistry 1998, 37, 16846-52.   
© 1998 American Chemical Society. 
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TrkA receptor, they function through indirect mechanisms.78-84 Small molecules 
related to cyclosporins such as GPI-1018 (A) mimic NGF responses, but do not act on 
either of the receptors (p75 and TrkA) and do require expression of them. They bind and 
affect immunophilins.80,81  SR57746A (B) induces NGF activities by increasing 
production and release of NGF.79  NG-061 (C) was shown to enhance and mimic trophic 
effects of NGF, with no evidence that it binds to TrkA.78 Kyanurenic acid derivatives 
such as D have been shown to inhibit the NGF/p75 interaction by binding to NGF.82  The 
K-252a (E) binds to an unknown target downstreaming the signal transduction pathway.83  
ALE-0540 (F) was found to acts as competitive inhibitor of NGF for binding to p75 and 
TrkA.84  It is believed that this compound does not bind to NGF but no direct binding to 
TrkA is evident. Although these compounds are active antagonists of NGF, they are none 
specific to neurotrophin receptor. Hence they can cause severe side effects if used as 
therapeutic agents.  
N
CF3
N
O
O
O
O
N
GPI-1018  (A)
O
NH
N O
MeO
NG-061 (C)
N CO2H
OMe
H2N
D
N N
H
N O
O
MeO2C OH
NO O
HN
OH
NO2
SR57746A  (B)
3
K-252a  (E) ALE-0540 (F)  
Figure 1.11.  Structures of compounds A-F. 
 
Alternatively, structure based designing of neurotrophin analogs can be used to 
develop compounds that are receptor specific. The sequence diversity observed on the 
loop regions of the neurotrophins suggests that these turns are important in defining the 
specificities of the hormone to the Trk receptors.  Many cyclic peptides derived from 
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these loop regions have been shown to function via the neurotrophin receptors. Disulfide-
linked cyclic hexapeptides based on NGF loops 2 (43-48) and 4 (92-97) have been shown 
to antagonize NGF by associating with TrkA and possibly p75.85-87   Other cyclic peptides 
derived from NGF have been reported to bind to p75, while those from the loop regions 
on BDNF were found to be BDNF antagonists.88-91  Only the cyclic compounds with β-
turn conformations  are active, the respective linear analogs exhibited no response.92,93   
This means that β-turn conformations are important in biological activities of these 
mimics. Therefore, it is important to investigate the possibility of using β-turn mimetics 
as a tool to mediate neurotrophin responses.  Such molecules can be useful in therapeutic 
applications and can also provide means to understand molecular basis of 
neurotrophin/receptor interaction. Tables 1.2 and 1.3 show the amino acid sequences of 
the turn regions of the neurotrophins that we are interested in. 
 
Table 1.2. Sequences of turn regions in NGF. 
Source Loop: residues i i +1 i + 2 i + 3 
Human      
 1:30-33 Asp Ile Lys Gly  
 2: 44-47 Ile  Asn  Asn Ser 
 3: 93-96 Asp  Gly  Lys  Gln 
Murine      
 1:30-33 Asp Ile Lys Gly  
 2: 44-47 Ile  Asn  Asn Ser 
 3: 93-96 Asp  Glu  Lys  Gln 
Bovine      
 1:30-33 Asp Ile Lys Gly  
 2: 44-47 Ile  Asn  Asn Ser 
 3: 93-96 Asp  Asn  Lys  Gln 
Guinea pig      
 1:30-33 Asp Ile Lys Gly  
 2: 44-47 Val  Asn  Asn Asn  
 3: 93-96 Asp  Gly  Lys  Gln 
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Table 1.3. Sequences of turn regions in NT-3. 
Source Loop: residues i i +1 i + 2 i + 3 
Human      
 1:29-32 Asp Ile Arg Gly  
 2: 42-45 Lys  Thr  Gly  Asn  
 3: 92-95 Glu Asn Asn Lys 
Mouse      
 1:29-32 Asp Ile Arg Gly  
 2: 42-45 Lys  Thr  Gly  Asn  
 3: 92-95 Glu Asn Asn Lys 
 
 
1. 4 Insulin-like Growth Factor and Receptors 
  The insulin-like growth factor (IGF) system comprises of two ligands (IGF-I and 
IGF-II), two receptors (IGF-IR and IGF-IIR) and at least six distinct binding proteins.94,95  
The IGF-I and IGF-II  promote growth and  differentiation of neurons and glial cells in 
the central nervous system.94  Both IGF-I and IGF-II bind to IGF-IR with high affinity 
(Kd = 1.5 and 3.0 nM respectively).94  The IGF-I receptor is a heterotetrameric 
glycoprotein composed of four subunits (2 α and 2 β) linked together by disulfide 
bridges.94,95  The IGF-II receptor is a monomeric receptor with extracellular domain made 
of 15 repeating cysteines and is identical to the cation-independent mannose-6-phosphate 
receptor.94  The IGF binding proteins (IGF-BPs) are multifunctional proteins that regulate 
the activities of the insulin-like growth factor (IGF).94-96  They play crucial roles in the 
transportation of IGFs in the blood stream, cerebrospinal fluid, and across the capillary 
barriers to the target cells.95,97-100  IGF-BP-3 and IGF-BP-5 also associate with an acid 
labile subunit (ALS), thereby increasing the half-life of IGFs.94  IGF-BPs  are present in 
the extracellular matrix or cell surface where they can enhance or inhibit  IGF activities.98  
They are also involved in a host of other IGF independent cellular activities.94,98,101 
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1.4.1 Interactions of IGF-I with IGF-IR or IGF-BPs 
     The IGFs and insulin consist of a small hydrophobic core formed by three helices 
stabilized by three disulfide bonds. The disulfide bonds in the single-chain IGFs are 
intramolecular while they connect the A and B chain in insulin.95,96  The A and B regions 
of the IGFs are connected by a loop known as the C-region (IGF-I; residues 29-41, Figure 
1.12).  This loop is found to be largely responsible for binding specificity of the IGF-IR 
for IGF-I.96  Mutation of Try 31 reduces the affinity of IGF-I for IGF-IR but has  no 
effect on its binding to either IR or IGF-BPs.95  The crystal structure of the IGF-I shows 
that C-region forms a type II β-turn. The B helix forms a type II` β-turn, which redirects 
the backbone of the B-helix into an extended region as shown in Figure 1.12.  Residues 
24-27 form a type VIII β-turn, allowing the C-region to extend away from the core of the 
molecule forming a type II β-turn (30–33) with Try 31 prominently exposed at the i+1.96 
 
Figure 1.12.  Ribbon structure of IGF-I. The B-region (residues 3-28) shown in blue, the 
C-region (residues 29-41) in light yellow, A-region (residues 42-62) in pink, and the D-
region (residues 63 and 64) in white. The disulfide bonds in yellow.* 
 
 
______ 
* Reprinted with permission from “ Crystal Structure of Human Insulin-like Growth Factor-1: Detergent Binding 
Inhibits Binding Protein Interactions” Vajdos, F. F.; Ultsch, M.; Schaffer, M. L.; Deshayes, K. D.; Liu, J.; Skelton, N. 
J.; de Vos, A. M. Biochemistry 2001, 40, 11022-11029. Copyright 2001 American Chemical Society. 
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 There are no crystal structures for the IGF-I/IGF-IR complex because the IGF 
receptor is a large trans-membrane protein, which is difficult to isolate and crystallize. 
The structures of the IGF complexes with IGF-BPs are available.94,96,101,102  These crystal 
structures, in addition to mutagenesis and NMR studies have been used to elucidate the 
hot-spots on the IGF-I.  Site directed mutagenesis studies mapping the binding sites of 
IGFs  for IGF-IR and  insulin receptor (IR) show that Tyr 60, Try 24, Phe 23, and Val 44 
are the  major determinants  for binding in IGF-I.95  Also Phe 25 and Arg 21 are 
important in the IGF-I binding.95  Structural studies on the miniNBP-5/IGF-I* complex 
indicate that Phe 23, Try 24, Phe 25, Val 44 and Try 60 form a fully solvent-exposed 
hydrophobic binding site for IGF-IR that is located on the opposite side of the IGF that is 
used to bind to miniIGFBP-5.95 
The binding of NBP-4, which was found to inhibit the binding of IGF-I to its 
receptor was studied (Figure 1.13).  The N-terminus of the NBP-4 was found to interact 
with the Phe 23, Tyr 24 Phe 25 of the IGF-I by filling the hydrophobic cleft and 
backbone C=O….NH H-bonding between the interacting proteins.95 
 
 
 
 
 
 
 
 
 
 
 
 
 
________ 
*NBP-5 refers to the N-terminal Domain of IGFBP-5  miniNBP-5 is a polypeptide from the NBP-5. 
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Figure 1.13. Ribbon plot of NBP-4 (blue) and IGF-I (green) complex. Residues shown in 
violet constitute the binding site for interaction with NBP-4 and those shown in red are 
determinants for binding to IGF-IR.* 
 
1.5 β-Turn Mimetics  
 β-turns are found in many of the ‘hot spots’ for molecular recognitions in 
proteins.103,104  Contacts between proteins in the immunoglobulin family, growth factors 
and adhesion molecules are known to often involve turn residues. Therefore, β-turns can 
be used as scaffolds in ligand design.  β-Turns are composed of four amino acid residues 
i to i+3 where a peptide chain reverses its direction.105 These turns are often stabilized by  
 
______ 
*Reprinted with permission from “Structural Basis for the Regulation of Insulin-like Growth Factors by IGF Binding 
Proteins”Siwanowicz, I.; Popowicz Grzegorz, M.; Wisniewska, M.; Huber, R.; Kuenkele, K.-P.; Lang, K.; Engh 
Richard, A.; Holak Tad, A. Structure 2005, 13, 155-67. © 2005 Elsevier Ltd 
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a 10-membered intramolecular hydrogen bond between the COi and the NHi+3 residues.  
β-Turns can be classified into subtypes based on torsional angles of the middle dipeptide 
backbones as shown in Table 1.4.104 Types I and II are the most common in proteins. 
 
Table 1.4.  Classification of β-turns 
 
i + 1
i + 2
i
i + 3
HN
R
1
N
H
O R
2
O
HN
C!O
C!
"i+1
"i+2 #i+2
#i+1
 
backbone torsional angle  (˚) β-turn type 
φi+1 ψi+1 φi+2 ψi+2 
I -60 -30 -90 0 
I' 60 30 90 0 
II -60 120 80 0 
II' 60 -120 -80 0 
IV bend with two or more angles with > + 40 from above turn 
VIa -60 120 -90 0 
VIb -120 120 -60 0 
VIII -60 -30 -120 -120 
 
Efforts have focused on design and development of β-turn mimetic of proteins.  
Many turn mimics have been based on mono- and bicyclic systems, designed to replace 
the turn hydrogen bond with covalent bond while retaining the side chain topology of the 
i+1 and i+2 residues (Figure 1.14).106-113   The critical side chains corresponding to the 
target turn are difficult to be incorporated into these mimetics, and the synthetic methods 
used to obtain these compounds makes it difficult for them to be incorporated into 
efficient production of libraries.112,114,115   
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Figure 1.14.  β-turn structure and the selected examples of β-turn mimetics. 
 
 In additon to synthetic ease, β-turn mimetics should be reasonably rigid to avoid 
entropic penalty upon binding to target proteins.  They should also be able to withstand 
proteolytic activities in the cell.  Our goal is to design and develop efficient solid-phase 
and solution-phase synthetic methods for β-turn peptidomimetics.  Our original design 
concept is based on “ring-fused C10” macrocyclic systems as shown in Figure 1.15.108  
These molecules are inspired by cyclic hexapeptide in turn-extended-turn conformations, 
but designed so that the extended part would be replaced by non-peptidic turn inducer 
moieties.  The turn inducers force turn conformation and improve bioavailability of the 
molecules. 
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Figure 1.15.  Comparison of cyclic hexapeptide with ring-fused C10 motif. 
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A more constrained peptidomimetics have been made by replacing the template 
amino acid with more rigid, non-peptidic turn inducing moieties.  Reduction of peptidic 
character can improve bioavailability of the mimics and also provide more reliable model 
of bioactive conformation to be used to develop later generations of therapeutic 
candidates.  Efficient solid-phase syntheses of these analogs have been developed.  The 
synthesis, conformation studies and their biological activities have been published. In 
order to further improve the bioavalaibilty of these compound, replacement of the natural 
peptidic parts of the C10 system with peptoids was employed. The synthesis and 
characterization of these peptoids is discussed in chapter II. 
 
1.6 Multivalent Ligands 
 Due to their size, small molecule ligands tend to exhibit low selectivity and weak 
binding since ligand/receptor interaction generally involves a large surface area.  Even 
though tight binding requires a relatively small fraction of a key region.  Fesik and others 
have demonstrated that two small molecules that bind a protein weakly can be linked to 
form higher affinity bifunctional ligands.116-123 This idea could be used to obtain 
functional mimic of NGF and NT-3.  Since activation of Trk receptor requires dimeric 
neurotrophins, monovalent turn analogs of neutotrophins are expected to be either   
antagonistic or inactive.  However, work in our group has shown that many monomeric 
β-turn mimetics can act as partial TrkA and TrkC agonists via synergizing with 
neurotrophins.  This suggests that a more complicated molecular pathway may be 
involved.   It is interesting to explore how bivalent turn analogs interact with receptors.  It 
is predicted that bivalent turn analogs that bind to one Trk molecules could be more 
potent antagonist and those that bind on two Trk molecules could gain full agonistic 
activities.  Indeed, dimers of cyclic peptides or large loops mimicking two turn regions of 
NGF have been shown to be TrkA agonists whereas those related monomeric compounds 
exhibited antagonistic responses.48,124,125  In addition to improving the activities of ligands, 
dimerization also increases the library pool of ligands from the existing pool (Figure 
1.14). 
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Figure 1.16.  (a) Production of homodimeric libraries from monomeric libraries, and (b) 
produduction of hetereodimeric libraries from monomeric libraries. 
 
There are many approaches reported for preparation of bivalent and multivalent  
peptidomimetics.   The approach shown in Scheme 1.2 involves solution-phase 
chemoselective linkage of unprotected peptidomemetics using triazine scaffold.  This is 
the most efficient approach and is being used in our group today to develop bivalent 
ligands.  The beauty of this technique does not only lie on the fact that the dimerization 
reaction is so clean that no purification is needed, it can also be applied to both solid 
phase and solution phase monomers.  
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Scheme 1.1. Triazole-scaffold dimerization. 
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Using this method, bivalent compound KB536 (Figure 1.15) was synthesized and 
was found to bind TrkA with an impressive dissociation constant of 20 ± 20 nM in a 
competitive binding assay with radiolabeled NGF (see chapter III). This result indicates 
that dimerization can greatly improve the activities of peptidomimetics. 
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Figure 1.17. Bivalent peptidomimetic with Kd = 20 ± 20 nM. 
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1.7. Summary 
The importance of protein-protein interaction to biological systems cannot be over 
emphasized.  Hence the great interest in this area of research.  Due to the large size of 
most proteins and natural ligand involved, most researchers have focused on the 
development of small molecule ligands that can interact with receptor proteins and trigger 
physiological activities.  
Research in our group has focused on synthesis of turn mimics of neurotrophins 
and TNFα.  Peptidomimetics that interact favorably with Trk receptor have been made.   
These peptidomimetics are C10 β-turn mimics that contain a peptidic turn part and non-
peptidic constrained region.  Due to the fact that these peptidomimetics contain natural 
peptides, they are less likely to survive proteolitic activities in cell.  
In order to overcome proteolytic activities, peptidomimetics that does not contain 
natural peptides are needed.  One way to achieve this goal is development of peptoids. 
Peptoids are proven to resist protealytic activies. Chapter II discusses the synthesis, 
characterization, and conformational analysis of peptoid libraries. 
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CHAPTER II 
 
CYCLIC SEMI-PEPTOID TURN MIMICS  
 
2.1 Introduction 
Progress in genomics and proteomics has lead to development of small molecules 
that play roles in activating or disrupting protein association, and other biological 
activities.  Many groups have shown interests in synthesis of mimics of protein secondary 
structures such as α-helixes and β-turns.126-128   Our group is interested in   
peptidomimetics that mimic β-turns of neurotrophins and TNFα.  We focus on 14-
membered macrocycles that involve dipeptides on the i +1 and i +2 region   
and a non-peptidic region to constrain the compound, thus reducing entropy on 
binding.108,129,130  Although compounds made in our group using the above idea have 
proven to be biologically potent, the need to develop compounds that are less peptidic, 
that could further diversify our library is crucial.   An obvious step is to develop non-
peptidic molecules with the same motif as the active peptides, which can increase the 
bioavailability without paying so much price for the activity.  We decided to develop 
peptoid macrocycles that retain the same backbones as the tested peptides. 
Peptoids have became increasingly used today in medicinal chemistry to mimic 
protein secondary structures, such as  α-helix, and β-sheets.131-133  They have also been 
employed in the mimics of nucleic acids and as affinity ligands in protein separations.133-
136  
 
2.2 Methods in Peptoids Synthesis 
 With the discovery of peptoids as a good substitute for natural peptides in drug 
discovery, chemists have focused over the years on development of efficient synthetic 
methods that could be used for large libraries of peptoid compounds.  Various methods 
involve either solution-phase synthesis or solid-phase synthesis, although solid-phase 
synthesis appears to be the most prevalent approach. 
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2.2.1 Solution-phase Approaches to Peptoids  
Solution phase synthetic methods are the less well explained for peptoid synthesis than 
solid phase methods. This might be due to the purification task often required for every 
step in the synthesis. Unlike solid-phase synthesis, solution-phase often requires extra 
steps that deal with either protection and deprotections, or reductions (reductive 
amination).  Nevertheless, solution-phase synthesis affords large-scale production of 
compounds at affordable price.  Two methods have been reported for solution-phase 
synthesis of peptoids; the N-alkylation method137 and the reductive amination method.138 
 The reductive amination method requires the imination of an aldehyde followed 
by reduction of the imine.  This can be done in two ways; the use of aldehydes as 
diversity elements on glycine139 (Scheme 3a), and the use of primary amines as diversity 
elements on α-aldocarboxylic acids (Scheme 3b).140,141 
 
Scheme 2.1. (a) Reductive amination with aldehydes as diversity elements,  
(b) Reductive amination with primary amines as diversity elements. 
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Scheme 2.1 continued 
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  While the use of aldehyde as diversity element poses a problem to chemist because  
there are limited supplies of aldehydes that can mimic specific amino acid side chains, 
the aldehyde in the second step of Scheme 3b tend to react and form tertiary amine.  This 
reduces the yield of the reaction. 
 The alkylation method is the most attractive method for synthesis of peptoids. 
Dialkylation is often prevented by protection of the amines.  The protecting group often 
used is the Nosyl protecting group, because it is orthogonal to most reaction conditions, 
and also makes N-alkylation easy.  This method shown in Scheme 4 often requires 
purification after deprotection of the Nosyl group.  Efforts in development of this method 
have improved the deprotection techniques that do not require purification.  This is 
achieved by using water solution thiol that will force the thioether byproduct into the 
aqueous phase during workup.137  
 
Scheme 2.2. Alkylation approach to solution-phase peptoid synthesis. 
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2.2.2 Solid-phase Approaches to Peptoid Synthesis 
This is the most widely used approach to peptoids.  With the introduction of 
automation and microwave synthesis, quicker and easier routes to peptoids are now 
available.   Both alkylation and reductive amination methods can be used to construct 
peptoids on solid support, but the reductive amination is less effective and is similar to 
the solution-phase amination method.  Hence this section will focus on the alkylation  
(submonomer) method,142 and the normal solid-phase peptide synthesis with N-
substituted glycine (monomer) method.141  
The monomer approach involves either Boc synthesis141 or the Fmoc 
synthesis,140,143,144 but the Fmoc synthesis is mostly used. Here N-alkylgycines are used as 
the building block in the construction of peptoids.  The setback to this method is the 
limited supply of the N-alkylgycines and the difficulty in preparing them.  The 
submonomer solid-phase synthesis is the most successfully used method for peptoid 
synthesis.  The success of this method could be attributed to the fact that primary amines 
required for diversity are abundant and the method can easily be automated. 
 
Scheme 2.3.  Monomer vs. submonomer solid phase synthesis according to Simon et 
al.144 and Zuckermann et al.142 
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Even with success achieved in the submonomer approach, work is still being done 
on further improving the coupling conditions.  Although the use of 
diisopropylcarbodiimide (DIC) as the activating agent is popular, many groups have also 
used acid halides.  Other improvements involve the use of automated systems at 35 
oC,145,146 and the use microwave irradiation.147,148  The microwave synthesis has 
impressively improved peptoid synthesis, each reaction step can be carried out in 1 min 
or less with significant improvement in yield and purity.  
 
2.3 Preparation of Primary Amines for Cyclic Peptoid Libraries 
Below is the list of primary amines building blocks for the peptoid libraries 
(Figure 2.1).  Each used to mimic a specific side chain in the turn regions of the protein 
of interest. 
 
NH2
H2N
O
NH2
NH2
H2N
OHH2N
H2N N
H
NH2
NH
I N
T
K R
HO
NH2
H2N
O
OH
G
S
MeN
O
OH
A
H2N OH
O
H2N NH2
O
Q
E
NH2
HO
Y
NH2
F
 
Figure 2.1.  Amine building blocks labeled with the amino acid residue they are used to 
mimic (red). 
 
2.3.1.  Protection of Alcohol Amines 
 The building blocks with alcohol residues needed for mimicking serine (S) and 
threonine (T) have to be protected to avoid O-alkylation during synthesis.  To protect the 
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alcohol group, the more reactive primary amine has to be first orthogonally protected.  
This is achieved by the nosylation of the amine.149 Scheme 2.4, shows how the alcohol 
amines were reacted with 2-nitrobenzosulfonyl chloride in ethanol, to afford the 
sulfonamides, which were then reacted with isobutylene in acidic condition to generate 
compounds 3 and 4.150 
 
Scheme 2.4.  Protection of alcohol amine building blocks; (a) serine building block and 
(b) threonine building block. 
a. 
HO
NH2
t-BuO
NHNs
(i) NsCl,  EtOH
(ii) isobutylene, H3PO4
BF3.Et2O  
           3 
 
 
b. 
HO
NH2
t-BuO
NHNs
(i) NsCl,  EtOH
(ii) isobutylene, H3PO4
BF3.Et2O  
        4 
 
2.3.2 Preparations of Arginine, Lysine and Tyrosine Building Blocks 
Preparation of primary amine blocks for lysine and arginine require mono 
coupling to diamines.  Arginine block was prepared by dropwise addition of a THF 
solution of N,N-bis-Boc-1-guanylpyrazole151 to an excess THF solution of 1,3-
aminopropane.  The mixture was stirred overnight, and the product recrystallized in 
ethanol (Scheme 2.5a). 
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 Lysine requires mono-Boc protection of 1,4-diaminobutane (Scheme 2.5b).  This 
is achieved by dropwise addition of ethanol solution of Boc-anhydride to an excess 
solution of 1,4-diaminobutane, and stirred overnight at ambient temperature to give 
amine 6 after purification.152 
The 4-aminomethylphenol needed for tyrosine building block was prepared by 
azidation of the corresponding benzyl alcohol followed by in situ Staudinger reduction of 
the azide (Scheme 2.5 c).153 
 
Scheme 2.5. Preparations of building blocks; (A) arginine building block, (B) lysine 
building block, and (C) tyrosine building block. 
A. 
H2N NH2
BocHN N
NBoc
N
H2N N
H
NHBoc
NBoc
Et3N,  THF  
    5 
 
B.   
 
H2N
NH2 H2N
NHBoc(Boc)2O, Et3N
MeOH  
           6 
C. 
OH
HO
NH2
HO
NaN3, PPh3
CCl4, DMF, 90
o
C  
     7 
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2.4 Preparation of Templates for Cyclization 
The templates for SN2 cyclizations were prepared from existing methods in our 
lab.  The template 7 was prepared by refluxing phthalide in bromic acid solution 
overnight as shown in Scheme 2.6.  The nitration of compound 8 in nitric acid and 
sulfuric acid mixture yielded a nitro-template 9, which is unstable and difficult to work 
with. 
  
Scheme 2.6.  Synthesis of templates for SN2 cyclization. 
 
O
O
OH
O
Br
30% HBr/AcOH
 
   8 
OH
O
Br
OH
O
Br
O2NHNO3 
H2SO4  
   9 
 
2.5 Optimization of Linear Peptoid Synthesis 
The syntheses of the peptoids were first attempted at room temperature and 
conventional heating using various concentrations of reagents, 14 but the yields and 
purities for the linear and cyclization reactions were low.  Kodadek, et al. reported a 
microwave assisted peptoid synthesis in which they used a domestic microwave 
instrument to generate pure compounds in minutes.147  This method could not be repeated 
on our (CEM: Discover) microwave instrument, which records a much higher 
temperature at 100 W than reported by Kodadek.  To generate an efficient microwave 
method, development of optimal microwave technique for both the acylation (Table 2.1) 
and alkylation  (Table 2.2) reactions were performed. 
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2.5.1 Optimization of the Acylation Step for Peptoid Syntheses 
After the initial coupling of the cysteine to the Rink amide MBHA resin via 
DIC/HOBt coupling protocol and removal of Fmoc protection, the acylation with 
bromoacyl moiety was studied to develop the best condition for this coupling step.  This 
is done using different reaction conditions as shown in Table 2.1 below.  The analyses of 
these reactions are uncertain, because of the possibility of the cleaved bromoacyl moiety 
to cyclize via SN2 attack by the free thiol.  Attempts to clarify which of the two products 
were present after cleavage proofed to be difficult because the amounts cleaved could 
only be used for mass spectrometric analysis.  The mass spectrum (EI) of entry 6 (Table 
2.1) was inconclusive as both molecular ions were present.  Since the initial HPLC 
analysis shows 99 % purity, it was necessary to check the HPLC after a long period of 
time.  The purity of the product in MeCN/H2O was reduced to 42% after 24 h of 
cleavage.  This means that the linear bromoacyl product was converting to the lactam 
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Table 2.1. Acylation conditions for peptoid synthesis. 
 
N
H
NH2
O
SMmt
O
H
N
O
SH
BrH2N OR
S
H
N
H2N
O
O
(i) BrCH2COOH
Activation
(ii) 90 %TFA /i-Pr3Si H 
H2O          
entry reactants DIC 
(M) 
DIEA 
(M) 
solvent temp 
(oC) 
time 
(mins) 
puritya 
(%) 
        
1 bromoacetyl bromide 
(3 eq) 
0 1 CH2Cl2 25 60 70 
2 bromoacetyl bromide 
(2 M) 
0 2 CH2Cl2 25 60 65 
3 bromoacetic acid  
(2 M) 
2 0 DMF 25 120 76 
4 bromoacetic acid    
(2 M) 
2 0 DMF 35 60 86 
5 bromoacetic acid     
(2 M) 
2 0 DMF 40 60 89 
6 bromoacetic acid     
(2 M) 
2 0 DMF 50 
(µω) 
1 99 
a Assessed by HPLC of crude product, monitored with ELS. 
 
2.5.2 Optimization of the Acylation/Alkylation Procedure for Peptoid Syntheses 
The resin bound bromoacyl amide from entry 6 in Table 2.1 was used to study the 
alkylation reactions (Table 2.2) 
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Table 2.2. Optimization of microwave-assisted peptoid synthesis. 
N
H
NH2
O
SMmt
O
H
N
O
SMmt
BrN
H
(i) BrCH2COOH
DIC, DMF, MW
50 oC, 1 min.   
O
H
N
O
SMmt
BrN
H
(i) Benzylamine
(ii) 90 %TFA /i-Pr3Si H 
H2O
O
H
N
O
SH
N
H
H2N
 
entry solvent temp 
(oC) 
time 
(min) 
puritya 
(%) 
     
1 DMF 25 120 53 
2 DMSO 25 120 55 
3 DMF 35 90 79 
4 DMF 40 60 85 
5 DMF 50 (µω) 1 99 
6 DMSO 50 (µω) 1 98 
a Assessed by HPLC of crude product, monitored at 254 nm via UV detector 
 
2.6 Synthesis of Linear Peptoids 
Microwave irradiation at 50 oC for 1 min (entry 5 on Table 2.2) was found to be 
the optimal procedure for the peptoid synthesis and was employed in this project.  
The deprotected cysteine or homocysteine bound resin is washed and treated with a 
solution of bromoacetic acid and DIC and irradiated with microwave.  Then the resin was 
washed and treated with a solution of primary amine and microwaved again.  This 
protocol is repeated again as shown in Scheme 2.7.  Blackwell and coworkers recently 
reported that microwave irradiation is not necessary for peptoid synthesis involving 
unhindered primary amines.  They reported being able to synthesize peptoids of high 
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quality within the same reaction time as in microwave, at room temperature.148  This is 
very interesting, since reactions we carried out during the early stages of this project at 
room temperature did not give us pure enough substrate to be used in macrocyclization 
after 2 h reaction time each.  This could mean that we have been leaving our reactions to 
run for an unnecessary amount of time with unnecessary heating.  
 
Scheme 2.7.  Synthesis of linear peptoids. 
 
N
H
NH2
O
SMmt
O R2'
H
N
O
SMmt
NHN
H
(i) BrCH2COOH
DIC, DMF
(ii) R2' NH2, DMF  
 
N
H
H
N
O
SMmt
N
O R2'
NH
O R1'
(i) BrCH2COOH
DIC, DMF
(ii) R1'NH2,  DMF  
 
2.6.1 Linear Peptoids with Alcohol Sidechains 
Microwave synthesis of linear peptoids in Scheme 2.7 above was not used for the 
addition of the (S) and (T) monomers for the compounds 1SG, SY and TG, because the 
removal of the nosyl of the precursors 3 and 4 to regenerate primary amines were not 
successful.149  The products were difficult to isolate.   To overcome this problem, the 
nosylated compound was alkylated to the resin bound bromoacetic amide substrate 
(Scheme 2.8).  The thioether byproducts after deprotection were washed away to generate 
pure linear dipeptoids. 
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Scheme 2.8. Synthesis of peptoids with nosyl amides. 
 
O R2'
H
N
O
SMmt
NHN
H
(i) BrCH2COOH
 DIC, DMF
(ii) R1'NHNs, DMF
 K2CO3
(iii) HOCH2CH2SH
 DBU, DMF  
 
N
H
H
N
O
SMmt
N
O R
2'
NH
O R
1'
 
 
    2.7  Formation of Peptidomimetics 1 
  The base mediated cyclization reactions were unsuccessful at room temperature as 
HPLC and mass spectra show mostly starting material after a 48 h reaction (table 2.3).  
This is surprising because it takes about 36 h of reaction time to obtain a macrocycle of 
normal 14-membered ring peptides via SN2, with high purity and yield. 108,129,154  The 
increased difficulty of peptoids to cyclize compared to peptides may be due to the fact 
that linear peptoids are more flexible (they vibrate and rotate much faster) and hence have 
higher entropy.155  To be able to obtain good quality macrocycles, optimization of the SN2 
cyclization protocol  was  carried out (Table 2.3). 
  The SN2 cyclization studies shown in Table 2.3 were performed using resin bound 
Cys-NAla-NAla (NAla = sacrosine, ie N-methylglycine).  This starting material was 
prepared on Rink-functionalized polystyrene resin with a conventional FMOC approach 
using DIC/HOBt couplings.  
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Table 2.3. Conditions for SN2 cyclization. 
 
N
O HN
C
O
N
O
SH
O
HN
Br
N
O
HN
CO
N
O
S
O
NH2
(ii) K2CO3, DMF
(iii) 90 % TFA / i-Pr3Si H
 H2O
1AA  
                                                                                  
entry temp( oC ) time 
(h) 
purity a 
(%) 
    
1 25 48 30 
2 35 48 53 
3 40 48 57 
4 50 (µω ) 0.17 97 
a Assessed by HPLC of crude product, monitored at 254 nm via UV detector 
 
 
 The result from entry 4 of Table 2.3 above was employed for macrocyclization reaction.   
The free thiol linear system was treated with excess K2CO3, DMF and irradiated with 
microwave for 10 min (Scheme 3).  The resin was washed dried in vacuo and cleaved to 
generate relatively pure compounds (Table 2.4).  The crude products were purified with 
preparative HPLC, lyophilized to powders in relatively good yield (Table 2.4). 
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Scheme 2.9. SN2 cyclization reaction.  
 
N
H
H
N
O
SMmt
N
O R
2'
NH
O R1' Br
Cl
O
i
Pr2NEt, CH2Cl2  
 
N
O HN
C
O
N
O
SMmt
R1'
R2'
O
HN
Br
(i) 3 % TFA / HSiiPr3
 CH2Cl2
(ii) K2CO3, DMF, MW  
50oC, 10 min
(iii) 90 % TFA / HSiiPr3 
 H2O  
N
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HN
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N
O
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1
R
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Table 2.4. Purity and yield data for the cyclic semi-peptoids 1. 
 
1 R1 R2 purity 
UV/ELS 
(%) 
yield 
(%) 
     
AA Me  Me  99/98 70 
EK CO2H  NH2  87/89 65 
GK H  NH2  100/98 60 
IK 
 
NH2  85/80 45 
IN 
 
CONH2  90/92 60 
IR 
 N
H
NH2
NH
 
89/80 80 
NK CONH2  NH2  80/82 68 
NN CONH2  CONH2  80/75 35 
QA CONH2  Me  91/70 55 
RA 
N
H
NH2
NH
 
Me  95/93 50 
SG OH  H  80/80 30 
SY OH  
OH  
86/84 45 
TG OH
 
H  75/78 52 
*Purity as assessed by HPLC of crude product, monitored by UV absorption at 254 nm and using an 
evaporative light scattering detector (ELS) 
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2.8 Formation of Peptidomimetics 2 
Since our group is interested in bivalent peptidomimetics, compounds 1 could not be 
used to make either bivalent compounds or monomeric compounds with chromophore, 
because there is no point of linker attachment.  To develop peptidomimetics with a point 
of linker attachment, the original compounds can be modified in two possible ways; 
nitration of the 2-bromomethylbenzoic acid template, or replacing the cysteine with a 
homocysteine and use 2-fluoro-5-nitrobenzoic acid as the template. 
The first method proved to be very difficult because 2-bromomethyl-5-nitrobenzoic 
acid is unstable and tend to form nitro phthalide.  Hence the second approach was used to 
generate peptidomimetics 2 via SNAr.  The macrocyclization method develop for the SN2 
systems was not efficient for the SNAr system, hence the need for an optimal protocol 
(Table 2.5).  The SNAr cyclization reaction was performed on a resin bound linear semi-
peptoid moiety constructed on a homocysteine scaffold (Scheme 2.1)  
 
Table 2.5. Microwave conditions for SNAr cyclization. 
 
N
O HN
C
O
N
O
O
HNO2N
HS
F
Ph
Ph
(ii) K2CO3, DMF
(iii) 90 % TFA / i-Pr3Si H 
 H2O
S
N
O
HN
CO
N
O
O
NH2
O2N
Ph
Ph
2FF  
entry temp 
(oC ) 
time 
(min) 
purity a 
(%) 
    
1 50 10 84 
2 60 10 90 
3 50 15 98 
aAssessed by HPLC of crude product, monitored at 254 nm via UV detector 
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 Scheme 2.10 shows how peptidomimetics 2 were generated.  The procedure is very 
much like that for peptidomimetics 1 except for longer reaction time for the SNAr 
cyclication step.  The yields and purities for 2 are relatively high (Table 2.6). 
 
Scheme 2.10. SNAr cyclization reaction. 
 
N
H
H
N
O
SMmt
N
O R
2'
NH
O R
1'
COCl
F
O2N
i
Pr2NEt, CH2Cl2  
N
O HN
C
O
N
O
R1'
R2'
O
HNO2N
MmtS
F
(i) 3 % TFA / HSiiPr3
 CH2Cl2
(ii) K2CO3, DMF, MW  
50oC, 15 min
(iii) 90 % TFA / HSiiPr3
 H2O
S
N
O
HN
CO
N
O
R1
R2
O
NH2
O2N
    
          2 
 
Table 2.6. Purity and yield data for the cyclic semi-peptoids 2. 
2 R1 R2 purity 
UVa/ELS 
(%) 
yield 
(%) 
     
ek CO2H  NH2  91/88 62 
ff 
  
99/98 70 
if 
  
95/93 50 
ik 
 
NH2  85/83 47 
ir 
 N
H
NH2
NH
 
89/80 40 
nn CONH2  CONH2  86/72 44 
qa CONH2  Me  93/77 52 
*Purity as assessed by HPLC of crude product, monitored UV absorption at 254 nm and using an 
evaporative light scattering detector (ELS). 
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2.9  Conformational Analysis 
Conformation analysis of small molecules is very important in medicinal and 
biological chemistry.  Although conformations of molecules in solution are not steady, it 
is possible to look at a prevailing population of conformers at a given time using 
techniques such as NMR.  This could be used to predict how the molecules would 
interact with specific receptors.  Approaches used in our conformation studies include 
NMR, CD, and QMD studies.  Our use of NMR was limited to temperature coefficient 
experiments because there are no NH and tertiary α-CH to look at in the i +1 and i +2 
regions for 2D NMR.  This was also a problem during QMD Studies (see section 2.9.3) 
 
2.9.1 Intramolecular Hydrogen Bonding 
Intramolecular H-bonding in peptides and proteins can be identified via a variable 
temperature NMR experiment.  Slope from plots of the amide chemical shift against 
temperature is referred to as the temperature coefficient (Tc), or NH temperature gradient 
(ΔδNH/ΔT).156  Temperature coefficient of amide protons in DMSO that are either 
involved in hydrogen bonding or shielded from solvent are greater than -3 ppb/K because 
of steric shielding.  Values of -3 to -6 ppb/K indicated intermediate protection, while 
fully exposed amide protons have high negative Tc values (-6 to -10 ppb/K).157,158  This 
technique does not provide identification of hydrogen bond acceptor, therefore careful 
consideration has to be taken in the interpretation of the data.  Amino acids such as Asp, 
Asn, Glu, and Gln contain side chains carbonyl which is a good hydrogen bond acceptor 
can skew the results of this experiment. 157,159      
Amide proton exchange experiment is another approach used to detect the 
existence of hydrogen bonds in peptide.159,160  Slow amide proton-deuterium (H/D) 
exchange indicates solvent shielded as a result of either steric protection or the presence 
of a hydrogen bond, while fast H/D exchange shows solvent exposed amide proton.159,161   
This method is not good for dictation of H-bonding in small peptides because aminde 
hydrogens of small peptides in DMSO/D2O are often exposed and hence tend to 
exchange too fast for useful information to be obtained from them.156   
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 The temperature coefficient for i +3 NH of peptidomimetics 1NK was determined 
in DMSO-d6 to be -4.7 ppb/K.  This indicates that the NH is not strongly involved in H-
bonding or shielded from solvent.  On the other hand the Tc for the i+3 NH of 
peptidomimetics 2FF measured in DMSO-d6 shows much higher value (-1.2 ppb/K) 
indicating a strong H-bonding or shielding from solvent. 
 
2.9.2 CD Studies 
Circular dichroism (CD) spectroscopy has been used to study protein secondary 
structures.162-165  CD characteristics of β-turn have been theoretically determined and 
classified into class A, B, and C spectra.165,166  Experimental studies of various peptides 
containing turn conformation revealed that type II β-turn conformation generally show 
class B CD spectra.162,164,167  These feature weak, negative n-π* bands near 225 nm, strong 
positive π-π* bands between 200-205 nm, and strong negative bands between 180-190 
nm.165   Types I and II' β-turn give class C spectra with a negative n-π* band near 220 
nm, a negative π-π* band near 210 nm, and a positive π-π* band near 190 nm.163,165,168  
In our CD studies the usual 20 % methanol in water used as the solvent system in 
turn mimics studies did not dissolve the semi-peptoid mimics.  Hence a 35% methanol in 
water with 1.0% NaHCO3 was used.  The spectrum (Figure 2.2) shows a positive peak 
200-205 nm and a negative peak near 190 nm for compound 1NK.  This is a class B 
spectrum indicating a possible Type II β-turn conformation for this compound.  On the 
other hand, compound 2FF shows a strong minimum at 210 nm and a maximum at ca 
225 nm (class C) indicating possible type I β-turn conformation.  
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Figure 2.2. CD spectra in 35% methanol, 1.0% NaHCO3 in water. 
 
2.9.3 Quenched Molecular Dynamic (QMD) Studies 
Molecular dynamics are used to predict conformational states available for a 
given compound at a given condition.  They are often used to complement NMR in 
determining the most prevalent conformational state for a molecule. 
Molecular simulation has been extensively applied to visualize preferred 
conformation of small molecules.  The quenched molecular dynamics (QMD) 
technique169,170 is used to generate structures during a high-temperature dynamic 
simulation.  A number of individual conformations from the molecular dynamics 
trajectory are periodically extracted and quenched via minimization to produce a 
conformational ensemble rather than a single conformation.  These conformations are 
sorted into subsets according to their structural properties (families), which are used to 
represent the most probable conformations of the molecules of interest. 
The QMD analysis of compounds 1NK and 2FF were performed.  Although the 
Φ and Ψ could not be measured due to lack of NH and tertiary α-CH in the i +1 and  
i +2  regions, the distances between  C=Oi and NHi+1, and between the  first carbons of 
the side chains  (β-atoms) were measured and compared to the ideal β-turn types.  The 
C=Oi---H-Ni+1 was measured to be 4.7 Å which is longer for H-bonding.  The β-atoms 
distance was found to be 5.34 Å, which is close to that of a type 1 β-turn (5.2 Å).  The 
Figure 2.3 shows the lowest energy structures for the peptidomimetics 1NK, and 2FF.   
Unlike 1NK, the distance C=Oi---H-Ni+3 for 2FF (2.05 Å) is close to hydrogen bonding 
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distances ideal for a β-turns (2.0 Å).  The simulated H-bonding distances for both 
compounds are consistent with the temperature coefficient data.  Also the distance 
between the turn sidechains for 2FF is close to type I distance (5.36 Å vs. 5.2 Å). 
 
   
A       B 
C O N HS       
Figure 2.3.  A. Simulated favored conformation of 1NK; B. Simulated favored 
conformation of 2FF. 
 
2.10 Summary 
This chapter focussed on the development of synthetic methods for the 
preparation of the semi- peptoid compounds.  After the primary amines and templates 
needed for the synthesis were prepared, optimization studies were performed for certain 
steps of the synthesis that were not optimal.  It was demonstrated that the solid phase 
synthesis of peptoids on polystyrene functionalized with Rink-linker proceed rapidly and 
efficiently if the acylation and alkylation reactions were irradiated with microwave at 50 
oC for 1 min.  The cyclization reactions were found to be extremely slow under thermal 
conditions but significantly improved with microwave irradiation at 50 oC.  The semi-
peptoids 1 and 2 were prepared and characterized.  Limited conformational analyses were 
performed on selected compounds (1NK and 2FF), and were found to mimic β-turns.  
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CHAPTER III 
 
BIOLOGICAL STUDIES 
 
 
3.1 Introduction 
All the bioassays were performed by Dr. Uri Saragovi and co-workers at McGill 
University in Canada.  Cell survival assays were the primary screening method used to 
access the potency of peptidomimetics.  The assay uses a culture cells overexpressed with 
the membrane receptor of interest in deprived serum.  The culture is then treated with 
solutions of compounds to see if cell growth is affected or not. The compounds were also 
injected into culture of other cells expressing receptor that are not targeted as control.171  
After leads are found in cell survival assay, they are subjected to FACS assay, 
competitive binding assays, and phosphorylation assay. 
 
3.2 Cell Survival Assays with the Semi-Peptoids 
 These are the first step in determining the activity of a compound.  They provide 
information on the agonism or antagonism, selectivity, specificity and toxicity. 
Antagonism occurs when non-cytotoxic compounds induces cell death, while agonism 
occurs where high level of survival is observed.  Agonism can also be tested by the 
ability of the compounds to rescue cells from apoptosis in a serum free media, in the 
absence of natural ligands.  Receptor specificity occurs if activity is observed in only 
cells expressing one receptor and not in cells that do not express that receptor (e.g. 
survival in NIH-TrkA but no survival in NIH-Trk C, and NIH-IGFIR).54 
 The testing of the semi-peptoids was a bit difficult due to the low water solubility 
of these compounds.  Hence DMSO/water mixture and Hank´s Balanced Salt Solution 
(HBSS) were used to dissolve them (see Appendix B).  It is important to mention that the 
results reported in this section are preliminary.  They need to be confirmed with at least 
three independent experiments.  Hence the error analyses reported might not be 
statistically significant.  They are calculated from 2 measurements of the same solution at 
2 different dates.  The NTF level employed in all the experiments was 5 % serum as 
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positive control (100 % survival).  The initial screens with 3 µM concentrations of the 
peptidomimetics indicated little or no activity (Tables 3.1a-c, and Figures 3.1-3.3).  This 
might be caused by low concentration of the compounds.     
  
Table 3.1a. Cell survival data of semi-peptoids dissolved in high concentration of 
DMSO. 
Comp’ds E25 cells 
(TrkA) 
 TrkC-C1 cells 
(TRKC) 
 IGF1-R cells  
(IGF-IR) 
 
 Serum free 
media 
Low NGF Serum free 
media 
Low  
NT-3 
Serum free 
media 
Low  
IGF-1 
None 0.00 0.00 
 
0.00 0.00 0.00 
 
0.00 
2FF 3.69±2.11 4.17±1.44 0.95 2.55 0.73±0.15 4.46±0.47 
2NN -0.07±0.45 -0.23±0.59 0.24 -2.20 0.73±0.26 -3.63±2.49 
1RA 0.55±0.66 -1.51±0.82  -0.30 -2.37 -1.04±0.47 -7.47±3.69 
1GK 1.60±1.17 -1.87±1.16 -0.12 -2.20 0.73±0.47 0.73±0.05 
1IR 0.75±0.91 -0.9±0.18 -0.36 -3.08 0.93±0.08 -2.28±1.66 
1TG 0.48±0.70 1.10 ±0.94 -0.12 -2.73 1.87±0.78 2.49±0.99 
50 % 
DMSO 
-1.16±0.12 0.23±0.25 0.30 -1.60 -2.59±0.83 -3.11±1.87 
40 % 
DMSO 
-0.80±0.10 3.01±1.25 1.20 -0.77 4.80 6.33 
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Figure 3.1.  Relative survival of cells, induced by semi-peptoids dissolved in a high 
concentration of DMSO (5% Serum as 100% survival).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 -  - 
 
54 
 
 
Table 3.1b. Cell survival data of semi-peptoids dissolved in low concentration of DMSO. 
Comp’ds E25 cells  TrkC-C1 cells  IGF1-R cells  
 Serum free 
media 
Low NGF Serum 
free 
media 
Low  
NT-3 
Serum 
free media 
Low  
IGF-1 
None 0.00 0.00 0.00 0.00 0.00 0.00 
2IK 2.02±1.34 2.14±1.43 1.22 -1.90 -
1.45±0.26 4.55±1.86 
1IK 3.97±2.35 4.96±2.65 -0.07 -0.14 -
2.48±1.35 5.01±0.03 
1EK 3.15±1.85  1.93±1.29 -0.36 0.68 -
3.72±1.91 1.29+1.90 
1SG -0.28±0.06 1.58±0.96 -0.34 -1.77 -
3.62±1.81 -6.10±4.86 
30 % 
DMSO 
 
0.46±0.62 
 
0.37±0.73 
 
-1.16 
 
-1.70 
-
4.75±2.03 2.76±0.56 
20 % 
DMSO 
 
-0.64±0.10 
 
-1.19±0.13 
 
-0.07 
 
-2.58 
-
2.89±1.49 
-
10.44±7.09 
10 % 
DMSO 
0.34±0.47 3.67±1.59 0.63 -3.67 -
3.00±1.19 -0.21±1.35 
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Figure 3.2.  Relative survival of cells, induced by semi-peptoids dissolved in a low 
concentration of DMSO (5% Serum as 100% survival).  
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Table 3.1c. Cell survival data of semi-peptoids dissolved in HBSS. 
Comp’ds E25 cells  TrkC-C1 cells  IGF1-R cells  
 Serum free 
media 
Low NGF Serum 
free 
media 
Low  
NT-3 
Serum 
free media 
Low  
IGF-1 
None 0.00 
 
0.00 
 
0.00 0.00 
 
0.00 
 
0.00 
2QA 
-1.53±0.67 5.75±2.04 -0.61 1.61 
-
1.17±0.80 -2.00±2.12 
2EK 0.86±0.81 3.05±1.70 -1.08 4.12 0.09±0.10 -4.75±3.55 
2IR 
-1.72±0.49 1.15±0.20 -1.01 2.40 
-
1.17±0.37 -1.17±1.50 
1QA 
-2.48±0.90 3.46±1.42 -1.48 0.63 
-
4.93±2.25 -6.30±3.74 
1NK 
-1.05±0.43 2.58±1.29 0.00 2.40 
-
4.63±2.28 -7.73±4.94 
1SY 6.01±3.23 4.68±1.63 -0.40 7.89 1.17±0.30 9.05±1.59 
1IN -0.05±0.48 3.75±1.96 0.07 1.25 0.75±0.64 -8.45±5.24 
 
 
 
Figure 3.3.  Relative survival of cells, induced by semi-peptoids dissolved in HBSS (5% 
Serum as 100% survival).  
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  After the initial screens with 3 µM concentration of compounds, the compounds 
with promising activities were selected.  The concentration of these compounds were 
increased to 10 µM and screened for survival activities (Tables 3.2a & b, Figures 3.4 & 
3.5).  The results of these screens show some survival, but these survivals are not 
restricted to any of the cell lines.  There are higher rates of survival in NIH- IGF1-R cells, 
especially with 2FF (23%).  This result could indicate a real potentiation (partial 
agonism) of the IGF1 receptor by 2FF, which has phenylalanine side chains.  
Phenylalanine is critical to IGF1 /IGF1-R interactions.  
 
Table 3.2a. Selected cell survival data of semi-peptoids dissolved in high concentration 
of DMSO or HBSS. 
Comp’ds NIH-TrkA cells   NIH-TrkC-C1 cells  NIH-IGF1-R cells  
 Serum 
free 
media 
Low NGF Serum 
free 
media 
Low  
NT-3 
Serum 
free media 
Low  
IGF-1 
None 0.00 0.00 0.00 0.00 0.00 0.00 
2FF 2.59 6.68 0.20 7.20 7.23 23.66 
1TG -1.44 2.37 -0.65 -2.27 1.86 12.05 
2QA -3.35 -1.56 0.00 1.32 1.75 12.05 
2EK -0.96 -1.08 -1.95 10.77 1.97 14.46 
SY 0.19 4.19 -0.58 5.58 2.52 8.00 
50 % 
DMSO -3.52 -0.93 -1.10 -1.36 -0.22 8.98 
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Figure 3.4.  Selected cell survival data of semi-peptoids dissolved in high concentration 
of DMSO or HBSS. 
 
Table 3.2b. Selected cell survival data of semi-peptoids dissolved in low concentration of 
DMSO. 
Comp’ds NIH-TrkA cells  NIH-TrkC-C1 cells  NIH-IGF1-R cells  
 Serum 
free media 
Low NGF Serum 
free 
media 
Low  
NT-3 
Serum 
free media 
Low  
IGF-1 
None 0.00 0.00 0.00 0.00 0.00 0.00 
2IK -4.67 -6.22 -1.61 -0.18 2.74 1.48 
1IK -2.01 -1.10 -1.01 11.57 5.91 14.98 
1EK -9.92 -10.63 -0.94 4.12 3.38 10.76 
10 % 
DMSO -11.67 -14.33 -0.07 0.56 1.90 3.38 
20 % 
DMSO -11.61 -15.24 -0.60 2.51 -1.27 6.96 
30 % 
DMSO -11.41 -13.10 -1.41 3.31 2.85 4.33 
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Figure 3.5. Selected cell survival data of semi-peptoids dissolved in low concentration of 
DMSO. 
 
3.3 Dimeric Frist Generation Petidomimetics 
 The dimers reported in these assays were originally prepared by Drs H. B. Li and 
M. Pattarawarapan in our lab, but re-prepared in collaboration with Samuel Reyes and 
Jing Liu.  The synthetic steps for a selected compound (KB536) are described below to 
illustrate how the library of dimers was put together.  The compound is made of two 
monomers a and b (Figure 3.6), whose synthesis is described in Schemes 3.1 and 3.2 
respectively. 
 
NH
O
N
H
HN
H2N NH
O
NHO
O
H2N
O
NH2
O
N
H
HN
H2N NH
O
HNNH
HN
O
O
H2N S
O
NH2
b
a  
Figure 3.6.  Monomers for KB536. 
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 The synthesis of both monomers follows fmoc synthesis on Rink functionalized 
polystyrene resin.  The aromatic amino acid template (compound a) was coupled to the 
resin using HBTU/HOBt coupling reagent mixture.  The second amino acid coupling is a 
bit difficult due to the less nucleophilic analine.  Hence PyBrop™ with 2,6-lutidine a 
method already worked out in our group in earlier publications, was used.129  The rest of 
the synthesis follows well known fmoc synthesis and SNAr cyclization. 
 
Scheme 3.1.  (i) Synthesis of monomer a, (ii) Linker and flouresciene triazine 
attachments. 
 
i. 
H2N
TrtO
OH
O
NHFmoc H2N
TrtO
O
20% piperidine
(i)
(ii) HBTU, HOBt, DIEA
DMF  
 
NH
OTrt
NHFmoc
H
N
O
O
O
(i) Fmoc-Arg(Mtr), PyBrop 
     2,6-lutidine 
(ii) 20% piperidine
(iii) Fmoc -Ile, DIC 
       HOBt, iPr2NEt
(i)  20% piperidine
(ii) 2-Fluoro-5-nitro-benzoylchloride
 iPr2NEt
N
H
MtrHN
NMtr
 
 
NH
O
NH2
O
NH
H
N
O
O
H
N
O
NH
OTrt
NO2
O
NH
H
N
O
O
O
F
(i) 1% TFA
(ii) K2CO3
(iii)SnCl2 .H2O
a'
N
H
MtrHN
NMtr
N
H
MtrHN
NMtr
 
 
F = Flourescein 
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Scheme 3.1 continued 
ii. 
 
NH
O
NH2
O
NH
H
N
O
O
H
N
O
Fmoc-Gly-Cl
Dmap, DIEA
DCM
NH
NHMtr
MtrN
NH
O
NH
O
NH
H
N
OO
H
N
O
O
NHFmoc
NH
NHMtr
MtrN
 
 
 
NH
O
NH
O
NH
H
N
OO
H
N
O
O
N
H
O
NFmoc
(i) 20% piperidine
(ii) Fmoc-Inp-OH
DIC, HOBt, DIEA
DMF
NH
NHMtr
MtrN
 
N
N
N
NHF
Cl
Cl
CCl3, DMSO
DIEA
(ii) 90 % TFA/ H2O/ TIS
NH
O
NH
O
NH
H
N
O
O
H2N
O
O
N
H
O
N
NH
NHMtr
MtrN
N N
N NHF
Cl
(i)
A  
 
Scheme 3.2 shows the synthesis of monomer b, which involves an SN2 cyclization.  The 
assembly of the linear peptide for this compound is easier and involves DIC/HOBt 
coupling and the usual acid chloride addition of the cyclization template. 
 
 
 
 
 -  - 
 
62 
Scheme 3.2.  (i) Synthesis of monomer b, (ii) Linker attachment. 
(i) 
NHFmoc
NH
O HN
O
NHFmoc
SMmt
(i) 20% piperidine
(iii  Fmoc-Cys(Mmt)
DIC, HOBt, DIEA
DMF/CH2Cl2
(iii) 20% piperidine
(iv)  Fmoc-gly, DIC
HOBt, DIEA
DMF/CH2Cl2  
 
NH
NHFmoc
H
N
O
O
N
H
MtrHN
NMtr
HN
O
O
HN
SMmt
Cl
Br
O
O2N
(i) 20% piperidine 
(ii) Fmoc-Arg(Mtr), DIC 
       HOBt, iPr2NEt
(iii) 20% piperidine
(iv) Fmoc -Ile, DIC 
       HOBt, iPr2NEt
(i)  20% piperidine
iPr2NEt, CH2Cl2
 
 
NH
NH
H
N
O
O
N
H
MtrHN
NMtr
HN
O
O
HN
SMmt
Br
O
NO2
O
N
H
HN
MtrHN NMtr
O
HNNH
HN
O
O
HN S
O
NH2
b'
(i) 1% TFA
(ii) K2CO3
(iii)SnCl2 .H2O
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Scheme 3.2 continued 
(ii) 
O
N
H
HN
MtrHN NMtr
O
HNNH
HN
O
O
HN S
O
NH2
B
O
N
H
HN
H2N NH
O
HNNH
HN
O
O
HN S
O
N
H
H
N
O
O
NH
O
N
H
HN
MtrHN NMtr
O
HNNH
HN
O
O
HN S
O
N
H
NHFmoc
O
Fmoc-Gly-Cl
Dmap, DIEA
CH2Cl2
(i) 20% piperidine
(ii) Fmoc-Inp-OH
DIC, HOBt, DIEA
DMF
(iii) 20% piperidine
(iv) 90% TFA / H2O
/ TIS
 
 
  After purification via preparative HPLC, compounds A and B were mixed in a base 
solution of DMSO at room temperature for overnight to generate pure KB536 (Scheme 
3.3). 
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Scheme 3.3.  Dimerization to form KB536 
A  + B
K2CO3, DMSO
25 
o
C, 24 h  
NH
O N
H
HN
H2N
NH
O
NH
O
OH2N
O
NH
O
N
H
NH
NH2HN
O
NH
HN
NH
O
O
NH2
S
O
N
H
H
N
O
N
O
O
N
H
O
N
N N
N
HN
O
COOH
O
HO  
KB536 
 
3.4 FACS Assays of Dimeric First Generation Peptidomimetic 
  The quantitative FACScan studies on cells indicated in Table 3.3 were 
performed using FITC- labeled peptidomimetics or anti-receptor mAbs as positive 
control (5C3 for TrkA and 2B7 for TrkC).  NIH-IGF1-R cells were used as negative 
control.135 
The results (Table 3.3) indicate that KB536 has the highest affinities to both TrkA 
and TrkC expressing cells even higher than the positive control.  The affinity of KB536 is 
highest for TrkC. 
 
 
 
 
 
 
 
 
 -  - 
 
65 
 
 
Table 3.3. Summary of FITC-peptidomimetic binding to TrkA-NIH cells or TrkC-NIH 
cells, by FACScan assays.  Mean channel fluorescence (MCF) of FITC-labeled ligands 
binding to TrkA or TrkC.  n= 3 ± sd.  Where no sd is shown, only 2 assays were carried 
out. 
 
FITC-Ligand NIH-TrkA NIH-TrkC 
   
5C3 mAb 290 ± 34 175 ± 37 
KB526 2 -2 
KB527 21 ± 9 -14 ± 1 
KB528 23 ± 2 -19 ± 3 
KB529 6 2 
KB530 85 ± 60 -12 ± 13 
KB531 60 ± 30 -2 ± 6 
KB532 -10 -24 
KB533 -3 3 
KB534 -3 -11 
KB535 111 ± 17 -20 ± 40 
KB536 335 ± 76 349 ± 61 
KB537 47 ± 13 9 ± 6 
KB538 70 ± 14 50 ± 26 
KB539 9 ± 11 2 ± 12 
 
3.5 Competitive Binding Assays 
The assays were based on 125I-NGF and mAb 5C3 binding competitions.172  The 
two compounds with the highest affinities in FACs assay (KB535 and KB536) were 
selected for this assay to determine their Kd values with TrkA.  The assays were carried 
out at constant 125I-NGF concentration (5 nM), which gives a maximum binding without 
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competition (16,500 cpms).  NGF, KB535, and KB536 were the competitive inhibitors 
used in this assay.  The IC50 of KB535 is 1000-fold higher than that of NGF as shown in 
Figure 3.1(10,000 nM vs 10 nM) indicating a Kd value of ~100 ± 20 nM. The IC50 of 
KB536 is 200-fold higher than NGF’ s competition, hence a Kd = ~ 20 ± 20 nM.  This is 
an impressive result and confirms the hypothesis that dimerization enhances activity of 
peptidomimetics.  Although the FACS result indicates a higher affinity of KB536 for 
TrkC, the Kd value of this compound for TrkC could not be determined due to the fact 
that radiolabeled NT-3 need for this assay is very pricey.  Also over-expressing and 
purification of TrkC cells in high quantity is expensive. 
 
 
Figure 3.7.  Binding Affinity of KB535 and KB536 for TrkA.  Shift of the data to the 
left is indicative of higher affinity. 
 
3.6   Summary 
Biological activities of peptidomimetics were reported.  The cell survival assay 
indicates a potentiation of IGF1-R cells by 2FF.  This indicates that 2FF could be an 
agonist of IGF-R.  Further experiments need to be performed to confirm this result.  Also 
the FACS and competitive binding show promising results for bivalent compounds, 
KB536 show high affinity for both TrkA and TrkC.   
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CHAPTER IV 
 
CONCLUSIONS 
 
 
The underlying concept in our ligand design is based on the turn regions of   TNF-
α  and neurotrophins, which are predicted to be involved in binding to their receptors.  
Strategies in the design and synthesis of these ligands were discussed.  Early  Ligands 
designed in our  group contain a peptidic turn region, which are predicted to have low 
bioavailability due to the fact that peptides are prone to proteolysis and low membrane 
permeability.  These new approaches involve preparation of new types of β-turn analogs 
with peptoids in the turn region to enhance bioavailability.  Two designs based on our 
early works on peptide microcycles were developed.  They involve the use of SN2 and 
SNAr for macrocycliztions. 
Chapter elaborated on the development of microwave synthetic methods, which 
allowed us to produce good quality compounds in less than 1 h of total reaction time. The 
conformational states of these semi-peptoids in solution (DMSO) were examined using a 
combination of NMR, CD, and molecular dynamic simulation studies (Chapter II).  The 
NMR and QMD studies were somewhat limited due to the fact that the important markers 
(NH and CαH) needed for unambiguous identification of turn types, are not present in 
these compounds.  There are no NH/CαH couplings to look at for dihedral angles and no 
NH/CαH or NH/NH ROESY cross peaks.  Nevertheless the conformational analyses of 
1NK and 2FF show that they indeed resemble β-turn. 
The cell survival assay for the  semi- peptoids did not show much result except 
for 2FF, which  shows agonist tendencies towards  IGF-IR.  This is an encouraging and 
needs to be confirmed with further testing.  The binding assay on the bivalent compounds 
shows that KB536 has an impressive Kd for TrkA and could even have higher   
dissociation constant with TrkC   as shown by the FACS assay.  These results further 
prove that dimerization is a great way to improve the activities of peptidomimetics. 
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APPENDIX 
 
 EXPERIMENTAL SECTION FOR CHAPTER II 
General Methods 
NMR spectra were recorded on INOVA 500 (500 MHz for 1H and 125 MHz 13C) and 
Mercury 300 (300 MHz for 1H) spectrometers.  NMR chemical shifts are expressed in 
ppm relative to internal solvent peaks, and coupling constants were m easured in Hz. 
ESI and MALDI mass spectra were obtained from the Mass Spectrometry Applications 
Laboratory at Texas A&M University.  Thin layer chromatography was performed using 
silica gel 60 F254 plates.  Flash chromatography was performed using silica gel (230-600 
mesh).  All chemicals were purchased from commercial supplier and used as received.  
For solid phase synthesis at room temperature, a manual control shaking apparatus and 
standard Fmoc and peptoid chemistry were used throughout.  A fritted polypropylene 
syringe (5-10 mL capacity) purchased from Torviq was used as the reaction vessel.  A 
CEM Discover microwave reactor was used for the peptoid synthesis with magnetic 
stirring at atmospheric pressure.  A 10 mL microwave reaction tube from CEM was used 
for the microwave reactions.  All the α-amino acids used had the L-configuration and 
were obtained from Advanced ChemTech except where otherwise indicated.  All primary 
amines are from Aldrich and Fluka.  Reverse phase high performance liquid 
chromatography (RP-HPLC) was carried out on Vydac C-18 columns (25 x 0.46 cm for 
analysis, 25 x 2.2 cm for preparative work) using Beckman system with the 32 Karat 
software.  The Sedex 55 was used for ELS detection, while the UV detectors used were 
Beckman System Gold 166 (215 and 254 nm) and System Gold 166P (215 nm) for 
analytical and preparative HPLC analyses respectively.  All HPLC analyses were done 
using gradient conditions.  The eluents used were solvent A (H2O with 0.1 % TFA) and 
solvent B (CH3CN with 0.1 % TFA).  Flow rates applied were 1mL/min and 10 mL/min 
for analytical and preparative HPLC respectively. 
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Preparation of Protected Amines and Templates 
 
N-(2-tert-Butoxyethyl)-2-nitrobenzenesulfonamide (3).  A solution of nosyl chloride 
(3.63 g, 16.37 mmol) in ethanol (10 mL) was added dropwise to a solution of 
aminoethanol (1.00 g, 16.37 mmol) in ethanol (15 mL).  The mixture was stirred at 25 oC 
for 2 h and monitored with TLC and ninhydrin.  The solvent was evaporated.  1H NMR 
analysis of the crude N-nosylaminoethanol indicated that it was sufficiently pure for the 
next step, so it was used for the next step without purification.  This product was 
dissolved in dichloromethane (25 mL) and cooled to -78 °C, then 0.25 mL of H3PO4 dried 
over P2O5 was added to the solution, stirred, and, while stirring, 0.5 mL of BF3.Et2O was 
added.  Isobutene (13 mL) was collected onto a 25 mL flask in a dry ice bath and added 
into the reaction mixture.  The reaction mixture was stirred in dry ice for 1.5 h and then 
allowed to stir overnight at room temperature. The reaction mixture was poured into a 2 
M ammonium hydroxide solution (50 mL) and extracted with dichloromethane.  The 
organic solution was dried over sodium sulfate, concentrated, and flash columned with 50 
% ethyl acetate in hexane eluent.  The product was dried to obtain a yellow powder (3.5 
g, 69 %). Rf  = 0.78 (50 % ethyl acetate in hexane); 1H NMR (300 MHz, CDCl3) δ 8.40-
8.36 (m, 1H), 7.97-7.93 (1, 2H), 7.72-7.69(m, 2H), 3.41 (t, J = 5.0 Hz, 2H), 3.23 (t, J = 
5.25 Hz), 2.01 (s, 1H), 1.09 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ 130.6, 130.1, 
117.6, 115.2, 155.0, 106.8, 65.6, 54.2, 42.5, 18.3; MS (ESI) calc’d for C12H18N2O5S 
(M+Na)+ 325, found 325.  
 
N-(2-tert-Butoxypropyl)-2-nitrobenzenesulfonamide (4).  This compound was 
prepared via a procedure similar to that described above.  Rf = 0.59 (30 % ethyl acetate in 
hexane); 1H NMR (300 MHz, CDCl3) δ 8.10 (d, J =3.0 Hz, 1H), 7.85-7.83 (m, 1H), 7.74-
7.70 (m, 2H), 3.29-3.23 (m, 3H), 1.96 (s, 1H), 1.18 (s, 9H), 1.11 - 0.99 (m, 3H); 13C 
NMR (75 MHz, DMSO-d6) 130.6, 117.6, 115.3, 115.1, 106.8, 100.8, 65.5, 55.7, 54.2, 
21.6, 18.5; MS (ESI) calc’d for C13H20N2O5S (M+Li+) 323, found 323. 
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1-Amino-4-[N2, N3–bis (tert–butoxycarbonyl)guanidino] propane (5).  A solution of 
1,3-diaminopropane (0.26 g) was prepared in 5% N,N’-diisopropylethylamine in THF (10 
mL).  Then a solution of N,N’-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine151 
(0.51 g) in THF (10 mL) was added dropwise with vigorous stirring.  The mixture was 
stirred at 25 oC overnight.  The solvent was evaporated and the product recrystallized in 
ethanol to obtain white crystals (0.29 g, 58 %), mp = 168-170 oC. Rf = 0.37 (10 % 
methanol, 1.0 % ammonium hydroxide, in chloroform).  The 1H NMR corresponds to the 
NMR reported in the literature.173  1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 2.1 Hz, 
1H), 6.29 (s, 1H), 3.33 (t, J = 5.85 Hz, 4H), 1.87 (m, 2H), 1.42 (s, 18H). 
 
(4-Aminobutyl)carbamic acid tert-butyl ester (6).  Compound was synthesized as 
reported by Gardner et.al.152  Rf = 0.67 (10 % methanol, 1.0 % ammonium hydroxide, in 
chloroform); 1H NMR (300 MHz, CDCl3) δ 4.92 (s, 1H), 2.99 (t, J = 6.2 Hz, 2H), 2.60 (t, 
J = 6.5 Hz, 2H), 1.35 (s, 9H), 1.34 –1.19 (m, 4H). 
 
4-Aminomethylphenol (7).  Compound synthesized as reported by Reddy et al.153  Rf = 
0.49 (20 % ethyl acetate, in hexane); 1H NMR (300 MHz, CDCl3) δ 7.35-7.23 (m, 4H), 
4.54 (s,  2H), 3.75 (bs, 2H);  
 
2-bromomethyl-benzoic acid (8). This compound was synthesized following a 
procedure that was developed in our group.174   1H NMR (300 MHz, CdCl3) δ8.03 (d, J = 
7.5 Hz, 1H), 7.59 – 7.57 (m, 2H), 7.48 (d, J = 7.0 Hz, 1H), 5.01 (s, 2H) 
 
2-bromomethyl-5-nitrobenzoic acid (9). This compound was synthesized following a 
procedure that was developed in our group.174   1H NMR (300 MHz, CdCl3) δ8.93 (s, 1H), 
8.29 (d, J = 7.0 Hz, 1H), 7.88 (d, J = 7.0 Hz, 1H), 5.23 (s, 2H) 
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Synthesis Procedures and Spectral Data for Compounds 1 
 
Rink amide MBHA resin (0.100 g, 0.72 mmol/g loading) was swelled with CH2Cl2 (10 
mL/g) in a 3 mL fritted syringe for 30 min.  The FMOC protecting group on the Rink 
handle was removed by treating the resin with 20 % piperidine in DMF (2 x ca 1.5 mL, 
10 min and then 15 min).  The resin was then washed with DMF (3x), MeOH (3x), DMF 
(1x), MeOH (1x), CH2Cl2 (2x), MeOH (2x), and CH2Cl2 (3x), after which, Fmoc-
Cys(Mmt)-OH (3 equiv.), DIC (3 equiv.), HOBt (3 equiv.), and DIEA (5 equiv.) in DMF 
(1.5 mL) were added.  After gentle shaking for 2 h, the reaction mixture was then drained 
and the resin was subjected to the washing cycle and Fmoc deprotection as previously 
described.  The resin was washed again, transferred to the microwave reaction vessel, and 
treated with bromoacetic acid (2M), DIC (2M), in DMF (ca 1.5 mL).  The vessel was 
placed in a microwave reactor and irradiated at 50 oC, 1 atm (open vessel), for 1 min.  
After washing with DMF (9x), the resin was then treated with primary amine (2 M), in 
DMF or DMSO (1.5 mL), and microwaved at 50 oC, 1 atm (open vessel), for 1 min.  The 
washing cycle with DMF were repeated.  The two microwave reactions and washing 
cycles were repeated.  Then the resin was transferred back to the syringe.  The 2-
bromomethylbenzoic acid moiety was introduced by treating the resin with 2-
bromomethylbenzoyl chloride (3 equiv.) and DIEA (3 equiv.) in CH2Cl2 (1.5 mL) for 40 
min.  The Mmt protecting group of the cysteine was removed by treatment with 1 % TFA 
and 5 % TIS in CH2Cl2 (2 mL, 7x 2 min each, or until yellow color disappeared).  After 
the resin was washed, macrocyclization was affected by adding K2CO3 (10 equiv.) in 
DMF and microwaving at 50 oC, 1 atm (open vessel), for 10 min.  The reaction mixture 
was then drained and the resin was washed with H2O (5x), DMF (3x), MeOH (3x), DMF 
(1x), MeOH (1x), CH2Cl2 (2x), MeOH (2x), and CH2Cl2 (3x) and then dried under 
vacuum for 4 h.  The peptide was cleaved from the resin by treatment with a mixture of 
90 % TFA, 5 % TIS, and 5 % H2O.  The cleavage solution was separated from the resin 
by filtration.  After most of the cleavage cocktail was evaporated in vacuo, the crude 
peptide was triturated using anhydrous ethyl ether.  The crude peptide was then dissolved 
in H2O/CH3CN mixture (1:1, 2 mL), purified via preparative HPLC and then lyophilized 
to give a powder obtained as a TFA salt. 
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N
O HN
C
O
N
O
S
CONH2
1AA  
1H NMR (500 MHz, DMSO-d6) δ 7.96 (d, J = 6.5 Hz, 1H), 7.85 (d, J = 7.0 Hz, 1H), 7.68 
(dd, J =7.0, 2.5 Hz), 7.39 (d, J =7.8 Hz), 7.32 (dd, J = 2.5, 7.8 Hz, 1H), 6.96 (s, 2H), 4.39-
4.35 (m, 1H), 4.18-4.06 (m, 4H), 3.78 (s, 2H), 2.87-2.76 (m, 8H); 13C NMR (125 MHz, 
DMSO-d6) δ 172.6, 171.6, 169.0, 168.6, 136.5, 131.9, 130.9, 130.1, 127.7, 124.9, 56.2 
53.0, 49.0, 37.8, 37.6, 34.4, 32.2; LRMS (APCI) calc'd for C17H22N4O4S (M+H+) 379, 
found 379; analytical HPLC homogeneous single peak, retention time = 20.9 min (5-70% 
B in 30 min). 
 
1H NMR 
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HPLC 
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N
O HN
C
O
N
O
S
CONH2
HO2C
H3N
1EK  
1H NMR (500 MHz, DMSO-d6) δ 8.17 (d, J =8.0 Hz, 1H), 7.65 (d, J = 7.8, 1H), 7.40 (dd, 
J = 7.7, 2.5 Hz, 3H), 7.20 (d, J = 7.7, 1H), 6.70 (bs, 3H), 6.56(dd, J = 7.8, 2.5 Hz, 1H),   
6.19 (s, 2H), 4.79-4.71 (m, 1H), 4.40-4.32 (m, 4H), 3.99(s, 4H), 3.80 (t, J = 6.0 Hz, 2H), 
3.41-3.34 (m, 2H), 3.13 (t, J = 5.0 Hz, 2H), 2.76 (d, J = 7.0 Hz, 2H),  2.29 (t, J = 6.0 Hz, 
2H), 1.91-1.81 (m, 2H), 1.58-1.42 (m, 2H); 13C NMR (125 MHz, DMSO-d6) δ 172.9, 
171.8, 171.5, 169.2, 168.8, 138.8, 135.9, 132.0, 130.6, 127.8, 124.7, 56.8, 52.2, 51.8, 
49.5, 46.9, 43.2, 36.5, 33.3, 26.5, 24.8, 22.9; MS (ESI) calc'd for C22H31N5O6S(M+H+) 
493, found 494; analytical HPLC: retention time = 18.2 min (8-70% B in 30 min), purity 
= 98 %. 
 
1H NMR 
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HN
O HN
C
O
N
O
S
CONH2
H2N
1GK  
 1H NMR (500 MHz, DMSO-d6) δ 8.17 (t, J = 7.6 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.74 
(d, J = 8.5 Hz, 1H), 7.45 (dd, J = 8.5, 3.8 Hz, 1H), 7.23 (d, J = 7.0 Hz, 2H), 7.02 (s, 2H), 
6.75 (dd, J = 3.8, 7.0 Hz, 1H), 4.71-4.58 (m, 1H), 4.21 (s, 2H), 3.82 (d, J = 7.6 Hz, 2H), 
3.58 (s, 2H), 3.18 (t, J = 7.4 Hz, 2H), 2.75 (d, J = 7.0 Hz, 2H), 2.31 (m, 2H), 2.14 (bs, 
2H), 1.57 (m, 4H); 13C NMR (125 MHz, DMSO-d6) δ 173.8, 172.6, 172.4, 169.2, 138.1, 
135.9, 131.6, 130.2, 127.5, 124.7, 56.8, 52.2, 49.5, 46.9, 33.2, 26.5, 25.0, 24.9, 23.0; 
LRMS (ESI) calc'd for C19H27N5O4S (M+H+) 422, found 422; analytical HPLC: purity= 
94 %, retention time = 14.1 min (5-95% B in 30 min). 
 
1HNMR 
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N
O HN
C
O
N
O
S
CONH2
H2N
1IK  
 1H NMR (300 MHz, DMSO-d6) δ 7.95(d, J = 5.2 Hz, 1H), 7.76 (d, J = 5.3 Hz, 1H), 7.44 
(dd, J =5.3, 3.0 Hz, 1H), 7.21 (d, J = 6.7 Hz, 1H), 7.01 (s, 2H), 6.71 (dd, J = 3.0, 6.7 Hz, 
1H), 4.60 (m, 1H), 4.24 (s, 2H), 4.15 (s, 4H), 3.75 (m, 1H), 3.17 (m, 2H), 2.76 (d, J = 6.5 
Hz, 2H), 2.20-2.00 (m, 2H) 1.84 (bs, 2H), 1.71-1.52 (m, 6H), 1.24 (d, J = 6.5 Hz, 3H), 
0.81 (t, J = 6.8 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 171.1, 167.9, 157.8, 157.5, 
136.2, 130.1, 129.6, 127.2, 126.4, 116.1, 55.9, 55.7, 54.2, 46.9, 39.4, 38.9, 33.6, 31.9, 
25.3, 25.1, 24.8, 17.4, 14.2; LRMS (ESI) calc'd for C23H35N5O4 S (M+H+) 478, found 478; 
analytical HPLC: purity = 97 %, retention time = 14.9 min (5-95% B in 30 min). 
 
1H NMR 
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N
O HN
C
O
N
O
S
CONH2
CONH2
1IN  
1in: 1H NMR (500 MHz, DMSO-d6) δ 8.45 (d, J =7.2 Hz, 1H), 7.72 (d, J = 7.0 Hz, 1H), 
7.36 (dd, J = 7.0, 2.5 Hz, 1H), 6.89 (dd, J = 2.5, 7.4 Hz, 1H), 6.77 (d, J = 7.4 Hz, 1H), 
6.36 (s, 2H), 6.03 (s, 2H), 4.22-4.41 (m, 1H), 4.18-3.97 (m, 6H), 3.45-3.21 (m, 3H), 2.77 
(d, J = 9.5 Hz, 2H), 1.84-1.72 (m, 2H), 1.28 (d, J = 7.5, 3H), 0.83 (t, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz, DMSO-d6) δ 173.1, 172.3, 171.7, 170.9, 168.8, 137.8, 136.5, 132.7, 
129.9, 127.4, 125.0, 57.2, 56.7, 52.7, 46.4, 41.8, 35.7, 31.4, 27.9, 19.9, 9.3; LRMS (ESI) 
calc'd for C21H29N5O5 S (M+H+) 464, found 464; analytical HPLC: homogeneous single 
peak, retention time = 16.8 min (8-70% B in 30 min). 
 
1H NMR 
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N
O HN
C
O
N
O
S
CONH2
NH
NH2HN
1IR  
1H NMR (500 MHz, DMSO-d6) δ 9.11 (t, J = 8.0 Hz, 1H), 8.76 (d, J = 7.5 Hz, 1H), 8.41 
(s, 1H), 8.17 (d, J = 7.6 Hz, 1H), 7.64 (s, 2H), 7.38 (d, J = 7.0 Hz, 1H), 7.23 (dd, J = 7.6, 
3.4 Hz, 1H), 7.06 (dd, J = 3.4, 7.0 Hz, 1H), 6.58 (s, 2H), 4.79-4.68 (m, 1H), 4.22-4.19 
(m, 4H), 3.79-3.71 (m, 1H), 3.61 (s, 2H), 3.19 (t, J = 7.2 Hz, 2H), 2.80 (d, J =7.8 Hz, 
2H), 2.15-2.10 (m, 2H), 1.58-1.52 (m, 4H), 1.40-1.37 (m, 2H), 0.88-0.79 (6, 4H); 13C 
NMR (125 MHz, DMSO-d6) δ 172.0, 171.9, 168.9, 165.8, 157.9, 137.8, 137.4, 135.6, 
130.1, 123.7, 116.4, 70.8, 60.1, 54.1, 52.2, 47.3, 39.2, 35.7, 33.6, 31.7, 25.7, 18.6, 13.5; 
MALDI MS calc'd for (M+H+) 506, found 506, (M+K+) 544 found 544; analytical HPLC 
purity = 97 %, retention time = 18.2 min (5-95% B in 30 min). 
 
1H NMR 
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N
O HN
C
O
N
O
S
CONH2
H2NOC
H2N
1NK  
1H NMR (500 MHz, DMSO-d6) δ 7.88 (d, J = 8.5, 1H), 7.43 (s, 2H), 7.05 (d, J = 8.5 Hz, 
1H), 6.96 (dd, J =8.5,4.8 Hz, 1H), 6.82 (d, J = 8.0 Hz, 2H), 6.51 (s, 2H), 6.43 (dd, J =4.8, 
8.0 Hz, 1H), 4.47  (s, 2H), 4.23 (m, 1H), 3.72 (s, 6H), 3.00 (t, J = 6.8 Hz, 2H), 2.37-2.32 
(m, 2H), 2.21-2.17 (m, 2H), 2.07 (d, 7.4 Hz, 2H), 1.23-1.12 (m, 4H); 13C NMR (125 
MHz, DMSO-d6) δ 174.0, 168.2, 159.7, 158.3, 156.5, 134.7, 130.9, 130.0, 122.2, 115.0, 
105.1, 99.0, 67.4, 56.0, 55.8, 52.5, 34.4, 32.4, 27.9, 22.5, 14.5; LRMS (ESI) calc'd 
(M+H+) 479, found 479; analytical HPLC homogeneous single peak, retention time = 
11.8 min (8-70% B in 30 min). 
 
 
1H NMR 
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N
O HN
C
O
N
O
S
CONH2
H2NOC
CONH2
1NN  
 1H NMR (500 MHz, DMSO-d6) δ 7.93 (d, J= 8.5, 1H), 7.43 (s, 2H), 7.08 (d, J = 7.5 Hz, 
1H), 6.98 (dd, J = 7.5, 3.5 Hz, 1H), 6.84 (d, J = 7.0 Hz, 1H), 6.55 (s, 4H), 6.40 (dd, J = 
7.0, 3.5 Hz, 1H), 4.51 (s, 1H), 4.22-3.19 (s, 2H), 3.77-3.72 (s, 8H),  3.00 (d, J = 7.2 Hz, 
2H); 13C NMR (125 MHz, DMSO-d6) δ 172.2, 172.0, 171.4, 169.6, 169.0, 166.7, 130.0, 
127.2, 126.9, 126.0, 119.3, 116.6, 60.4, 57.3, 54.2, 47.2, 43.8, 29.7, 28.3; LRMS (ESI) 
calc'd for C19H24N6O6S (M+H+) 465, found 465; analytical HPLC; homogeneous single 
peak, retention time = 16.8 min (5-95% B in 30 min). 
 
1H NMR 
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N
O HN
C
O
N
O
S
CONH2
H2NOC
1QA  
 1H NMR (500 MHz, DMSO-d6) δ 8.80 (d, J = 8.0 Hz, 1H), 8.41 (d, J = 7.8 Hz, 1H), 7.86 
(dd, J =4.0, 7.5 Hz, 1H), 7.68 (s, 2H), 7.37 (d, J = 7.5 Hz, 1H), 7.22 (dd, J =4.0, 7.8 Hz, 
1H), 6.58(s, 2H), 4.62-4.38 (m, 1H), 4.49 (s, 2H), 4.26-4.21 (m, 4H), 3.74 (t, J = 7.4 Hz, 
2H), 3.21(d, J = 8.5 Hz, 2H), 3.00 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H); 13C NMR (125 MHz, 
DMSO-d6) δ 172.7, 172.5, 172.2, 171.5, 168.3, 136.1, 132.0, 131.9, 130.2, 127.4, 125.1, 
55.7, 54.2, 50.5, 45.1, 42.5, 37.8, 34.9, 33.6; MS (ESI) calc’d for C19H25N5O5S (M+H+) 
436, found 436; analytical HPLC purity = 98 %, retention time = 15.7 min (5-95% B in 
30 min). 
 
1H NMR 
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N
O HN
C
O
N
O
S
CONH2
NH
NH2
HN
1RA  
1H NMR (500 MHz, DMSO-d6) δ 9.09 (t, J = 7.2 Hz, 1H), 8.71 (d, J = 7.8 Hz, 1H), 8.44 
(d, J  = 8.0 Hz, 1H), 8.18 (s, 1H), 7.65 (s, 2H)), 7.37 (dd, J =8.0, 5.5 Hz, 1H), 7.21 (d, J  
= 8.5 Hz, 1H), 7.06 (dd, J  = 8.5, 5.5 Hz, 1H), 6.60 (s, 2H), 4.72-4.78 (m, 1H), 4.22-4.19 
(m, 4H), 3.64 (s, 2H), 3.18 (t, J = 7.5 Hz, 2H), 2.99 (s, 3H), 2.80 (t, J = 7.0 Hz, 2H), 
2.15(m, 2H), 1.74 (m, 2H); 13C NMR (125 MHz, DMSO-d6) δ 172.0, 171.9, 168.1, 168.0, 
166.3, 137.8, 137.1, 130.1, 130.0, 129.9, 126.8, 59.8, 55.7, 54.0, 47.2, 33.4, 31.7, 27.9, 
25.6, 23.7; LRMS (MALDI) calc'd (M+H)+ 464, found 464; analytical HPLC: purity = 91 
%, retention time = 15.9 min  (5-95% B in 30 min). 
 
1H NMR 
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Procedure for solid phase synthesis of Peptidomimetics 1sg, sy, and tg:  Rink amide 
HMBA resin (0.100 g, 0.72 mmol/g loading) was swelled with CH2Cl2 (10 mL/g) in a 3 
mL fritted syringe for 30 min.  The FMOC protecting group on the Rink handle was 
removed by treating the resin with 20 % piperidine in DMF (2 x 1.5 mL, 10 min and then 
15 min).  The resin was then washed with DMF (3x), MeOH (3x), DMF (1x), MeOH 
(1x), CH2Cl2 (2x), MeOH (2x), and CH2Cl2 (3x), after which, Fmoc-Cys(Mmt)-OH (3 
equiv.), DIC (3 equiv.), HOBt (3 equiv.), and DIEA (5 equiv.) in DMF (1.5 mL) were 
added.  After gentle shaking for 2 h, the reaction mixture was then drained and the resin 
was subjected to the washing cycle and Fmoc deprotection as previously described.  The 
resin was washed again, transferred to the microwave reaction vessel, then treated with 
bromoacetic acid (2M), DIC (2M.), in DMF (1.5 mL) and microwaved at 50 oC, 1 atm 
(open vessel), for 1 min.  After washing with DMF (9x), the resin was treated with 
primary amine (2 M), in DMF or DMSO (1.5 mL), and microwaved at 50 oC, 1 atm (open 
vessel), for 1 min. The washing cycle with DMF were repeated.  The microwave 
acylation reaction with bromoacetic acid was repeated and washed.  The resin bound 
product was treated with N-(2-tert-Butoxyalkyl)-2`-nitrobenzenesulfonamide (2 M) in 
DMSO and K2CO3 (10 equiv.).  The vessel was irradiated with microwave at 50 oC for 2 
min.  The resin was transferred back to the syringe and washed.  Then 2-mecaptoethanol 
(5 equiv.), and DBU (5 equiv.) in DMF (1.5 mL) were added to the syringe and shaken 
for 30 min.  The process was repeated for another 30 min and then the resin was washed 
with DMF (3x), MeOH (3x), DMF (1x), MeOH (1x), CH2Cl2 (2x), MeOH (2x), and 
CH2Cl2 (3x).  The 2-bromomethylbenzoic acid moiety was introduced by treating the 
resin with 2-bromomethylbenzoyl chloride (3 equiv.) and DIEA (3 equiv.) in CH2Cl2 (1.5 
mL) for 40 min.  The Mmt protecting group of the cysteine was removed by treatment 
with 1 % TFA and 5 % TIS in CH2Cl2 (2 mL, 2 min 7x, or until yellow color 
disappeared).  After the resin was washed, macrocyclization was affected by adding 
K2CO3 (10 equiv.) in DMF and microwaved at 50 oC, 1 atm (open vessel), for 10 min.  
The reaction mixture was then drained and the resin was washed with H2O (5x), DMF 
(3x), MeOH (3x), DMF (1x), MeOH (1x), CH2Cl2 (2x), MeOH (2x), and CH2Cl2 (3x) and 
then dried under vacuum for 4 h.  The peptide was cleaved from the resin by treatment 
with a mixture of 90 % TFA, 5 % TIS, and 5 % H2O.  The cleavage solution was 
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separated from the resin by filtration.  After most of the cleavage cocktail was evaporated 
in vacuo, the crude peptide was triturated using anhydrous ethyl ether.  The crude peptide 
was then dissolved in H2O/CH3CN mixture (1:1, 2 mL), purified via preparative HPLC 
and then lyophilized to give a brownish powder obtained as a TFA salt.  
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N
O HN
C
O
N
O
S
H
CONH2
HO
1SG  
1H NMR (500 MHz, DMSO-d6) δ 8.59 (d, J = 8.0 Hz, 1H), 8.18 (t, J = 8.5 Hz, 1H), 7.67 
(d, J = 7.4 Hz, 1H) 7.38 (dd, J = 7.5, 3.0 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.06 (dd, J 
=3.0, 7.4 Hz, 1H), 6.57 (s, 2H), 4.39-4.33 (m, 1H), 4.00 (s, 2H), 3.84 (d, J = 8.5 Hz, 2H), 
3.62 (s, 2H), 3.19 (t, J = 6.0 Hz 2H), 2.99 (t, J = 6.0 Hz, 2H), 2.76 (d, J = 7.0 Hz, 2H); 
13C NMR (125 MHz, DMSO-d6) δ 172.7, 170.0, 169.9, 167.1, 137.0, 136.8, 127.0, 126.8, 
126.7, 112.0, 74.0, 64.8, 55.8, 48.6, 48.0, 34.9, 27.2; LRMS (MALDI) calc'd (M+H)+ 
395, found 395; analytical HPLC: purity = 93 %, retention time = 12.7 min (5-90% B in 
25 min).  
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N
O HN
C
O
N
O
S
CONH2
HO
OH
1SY  
1H NMR (500 MHz, DMSO-d6) δ 8.60 (d, J = 7.8 Hz, 1H), 7.64 (d, J =8.5 Hz, 1H), 
7.39(dd, J = 8.5, 3.5 Hz, 1H), 7.22 (dd, J = 3.5, 8.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 1H), 
6.77 (d, J = 7.0 Hz, 2H), 6.56, (d, J = 7.0 Hz, 2H), 6.15 (s, 2H), 4.78-4.71 (m, 1H), 4.39 
(s, 2H), 4.23-4.19 (m, 4H), 3.62 (s, 2H), 3.19 (t, J = 7.5 Hz, 2H), 3.00 (t, J = 7.5 Hz, 2H), 
2.77 (d, J = 8.5 Hz, 2H); 13C NMR (125 MHz, DMSO-d6) δ 172.8, 170.5, 170.0, 169.9, 
155.5, 137.4, 137.3, 132.0, 132.1, 126.8, 126.7, 126.6, 112.0, 111.9, 67.4, 60.0, 59.9, 
53.8, 53.1, 46.3, 35.6, 27.7; MALDI MS calc'd for (M+H+) 501, found 501; analytical 
HPLC: purity = 89 %, retention time = 16.7 min (5-95% B in 30 min). 
 
1H NMR 
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N
O HN
C
O
N
O
S
H
CONH2
HO
1TG  
 1H NMR (500 MHz, DMSO-d6) δ 8.59 (d, J = 7.0 Hz, 1H), 8.02 (t, J = 7.8 Hz, 1H), 7.67 
(d, J =7.5 Hz, 1H), 7.37 (dd, J = 3.7, 8.0 Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 7.04 (dd, J = 
3.7, 7.5 Hz, 1H), 6.57(s, 2H), 4.78-4.69 (m, 1H), 4.40 (s, 2H), 4.23 (d, J = 7.8 Hz, 2H), 
3.99-3.94 (m, 1H), 3.62 (s, 2H), 3.20 (d, J = 9.5 Hz, 2H), 2.78 (d, J = 8.5 Hz, 3H), 1.39 
(bd, J = 8.5 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 172.7, 170.0, 169.9, 166.8, 
137.1, 136.8, 126.7, 126.3, 112.0, 111.9, 74.0, 64.8, 55.5, 48.6, 48.0, 35.0, 27.0, 21.6; 
LRMS (MALDI) calc'd (M+Na+) 431, found 431; analytical HPLC: purity = 93 %, 
retention time = 9.8 min (8-70% B in 30 min). 
 
 1H NMR 
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Synthetic Procedures and Spectral Data for Compounds 2 
 
Rink amide MBHA resin (0.100 g, 0.72 mmol/g loading) was swelled with CH2Cl2 (10 
mL/g) in a 3 mL fritted syringe for 30 min.  The FMOC protecting group on the Rink 
handle was removed by treating the resin with 20 % piperidine in DMF (2 x 1.5 mL, 10 
min and then 15 min).  The resin was then washed with DMF (3x), MeOH (3x), DMF 
(1x), MeOH (1x), CH2Cl2 (2x), MeOH (2x), and CH2Cl2 (3x), after which, Fmoc-
Cys(Mmt)-OH  (3 equiv.), DIC (3 equiv.), HOBt (3 equiv.), and DIEA (5 equiv.) in DMF 
(1.5 mL) were added.  After gentle shaking for 2 h, the reaction mixture was then drained 
and the resin was subjected to the washing cycle and Fmoc deprotection as previously 
described.  The resin was washed again, transferred to the microwave reaction vessel, 
then treated with bromoacetic acid (2M.), DIC (2M.), in DMF (1.5 mL) and irradiated 
with microwave at 50 oC, 1 atm (open vessel), for 1 min.  After washing with DMF (9x), 
the resin was then treated with primary amine (2 M.), in DMF or DMSO (1.5 mL), and 
microwaved at 50 oC, 1 atm (open vessel), for 1 min.  The washing cycle with DMF was 
repeated.  Then the two microwave reactions and washing cycles were repeated.  The 
resin was transferred back to the syringe and 2-fluoro-5-nitrobenzoic acid moiety was 
introduced by treating the resin with 2-fluoro-5-nitrobenzoyl chloride (3 equiv.) and 
DIEA (3 equiv.) in CH2Cl2 (ca 1.5 mL) for 40 min.  The Mmt protecting group of the 
homocysteine was removed by treatment with 1% TFA and 5% TIS in CH2Cl2 (2 mL, 7x 
2 min each, or until yellow color disappeared).  After the resin was washed, 
macrocyclization was affected by adding K2CO3 (10 equiv.) in DMF and microwaved at 
50 oC, 1 atm (open vessel), for 15 min.  The reaction mixture was then drained and the 
resin was washed with H2O (5x), DMF (3x), MeOH (3x), DMF (1x), MeOH (1x), CH2Cl2 
(2x), MeOH (2x), and CH2Cl2 (3x) and then dried under vacuum for 4 h.  The peptide 
was cleaved from the resin by treatment with a mixture of 90 % TFA, 5 % TIS, and 5 % 
H2O.  The cleavage solution was separated from the resin by filtration.  After most of the 
cleavage cocktail was evaporated in vacuo, the crude peptide was triturated using 
anhydrous ethyl ether.  The crude peptide was then dissolved in H2O/CH3CN mixture 
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(1:1, 2 mL), purified via preparative HPLC and then lyophilized to give a powder 
obtained as a TFA salt. 
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N
O
HN
C
O
N
O
CONH2S
O2N
HO2C
H3N
2EK  
1H NMR (500 MHz, DMSO-d6) δ 8.98 (d, J = 7.6 Hz, 1H), 8.71 (s, 1H), 8.16 (d, J = 7.5 
Hz, 1H), 7.80 (d, J = 7.5 Hz, 1H), 7.45 (bs, 3H), 6.58 (s, 2H), 4.39-4.36 (m, 1H), 4.18-
4.07 (m, 4H), 3.60 (t, J = 6.0 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 2.98 (t, J = 5.3 Hz, 2H), 
2.81 (t, J = 6.0 Hz, 2H), 2.22 (t, J = 8.0 Hz, 2H), 1.87-1.79 (m, 2H), 1.58-1.47 (m, 4H); 
13C NMR (125 MHz, DMSO-d6) δ 174.0, 161.7, 159.5, 159.2, 158.9, 144.7, 142.2, 135.0, 
130.6, 128.1, 125.4, 65.8, 56.0, 54.5, 51.4, 51.2, 42.5, 36.5, 32.4, 27.9, 25.2, 21.6; 
MALDI MS calc'd for C22H30N6O8S (M+H+) 539, found 539; analytical HPLC purity = 
95%, retention time = 13.0 min (5-95% B in 30 min). 
 
 
1H NMR 
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COSY 
 
 
13C NMR 
 
 
HPLC 
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N
O HN
C
O
N
O
CONH2
SO2N
2FF  
1H NMR (500 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.22 (d, J = 7.0 Hz, 1H), 7.77 (d, J = 8.5 
Hz, 1H), 7.40-7.35 (m, 4H), 7.28-7.19 (m, 6H), 6.86 (d, J = 7.0 Hz, 1H), 6.58 (s, 2H), 
4.98-4.92 (m, 1H), 4.76-4.65 (s, 4H), 4.11-4.18 (s, 4H), 2.76 (t, J = 6.5 Hz, 2H), 2.18-
2.22 (m, 2H); 13C NMR (125 MHz, DMSO-d6) δ 174.5, 172.7, 170.2, 168.8, 145.6, 137.9, 
137.7, 134.7, 129.4, 129.3, 129.1, 129.0, 128.7, 128.2, 128.1, 127.9, 127.4, 124.9, 54.3, 
52.8, 52.7, 49.9, 48.5, 30.4, 28.9; MALDI MS calc'd for C29H29N5O6S (M+H+) 576, found 
576; analytical HPLC: purity = 99 %, retention time = 20.2 min (8-70% B in 30 min). 
 
 
1H NMR 
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COSY 
 
13C NMR 
 
HPLC 
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N
O HN
C
O
N
O
CONH2
SO2N
2IF  
 
1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J = 7.4 Hz, 1H), 8.71 (s, 1H), 8.39 (d, J = 7.2 
Hz, 1H), 7.38 (d, J = 10.0 Hz, 2H), 7.24 – 7.17 (m, 3H), 6.83 (d, J = 7.2 Hz, 1H), 6.58 (s, 
2H), 4.72-4.68 (m, 1H), 4.62 (s, 2H), 4.39-4.35 (m, 4H), 3.90-3.87 (m, 1H), 2.79 (t, J 
=6.9 Hz, 2H), 2.21-2.17 (m, 2H), 1.23-1.17 (m, 2H), 0.95-0.84 (m, 6H); 13C NMR (125 
MHz, MeCN-d3) δ 170.4, 161.5, 158.8, 156.2, 144.6, 144.1, 137.1, 136.6, 129.3, 128.7, 
128.5, 127.2, 125.0, 122.4, 67.5, 55.4, 53.7, 49.8, 34.9, 31.6, 27.9, 22.1, 17.4, 13.1; 
MALDI MS calc'd for C26H31N5O6S (M+H+) 542, found 542; analytical HPLC: purity = 
93 %, retention time = 19.3 min (8-70% B in 30 min). 
 
1H NMR 
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COSY 
 
13C NMR 
 
HPLC 
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N
O HN
C
O
N
O
CONH2
S
H3N
O2N
2IK  
1H NMR (500 MHz, DMSO-d6) δ 9.00 (d, J = 7.0 Hz, 1H), 8.66(s, 1H), 8.18 (d, J = 8.0 
Hz, 1H), 7.75 (d, J =8.0 Hz, 1H), 7.21 (bs, 3H), 6.51 (s, 2H), 4.57-4.73 (m, 1H), 4.18-
4.13 (m, 4H), 3.82-3.78 (m, 1H), 3.57 (t, J = 6.5 Hz, 2H), 3.18-3.15 (m, 2H), 2.77 (t, J = 
5.5 Hz, 2H), 2.11-2.08 (m, 2H), 2.02-1.99(m, 2H), 1.57-1.54 (m, 2H), 1.47-1.42 (m, 2H), 
0.79-0.71 (m, 6H); 13C NMR (125 MHz, DMSO-d6) δ  174.1, 169.0 163.0, 161.2, 137.6, 
130.4, 126.9, 124.3, 117.6, 115.2, 65.1, 61.4, 55.7, 54.2, 42.5, 42.0, 36.4, 31.8, 28.2, 25.3, 
24.8, 18.3, 12.7; MALDI MS calc'd for C23H34N6O6S (M+H+) 523, found 523; analytical 
HPLC purity = 95 %, retention time = 17.4 min (5-95% B in 30 min). 
 
 
1H NMR 
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13C NMR 
 
HPLC 
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O
NH
NH2HN
N
O HN
C
O
N
CONH2
SO2N
2IR  
1H NMR (500 MHz, DMSO-d6) δ 9.17 (s, 1H), 8.99 (d, J = 8.5 Hz, 1H), 8.63 (s, 1H), 
8.38 (t, J = 7.5 Hz, 1H), 8.17 (d, J = 6.8 Hz, 1H), 7.76 (d, J = 6.8 Hz, 1H), 7.97 (s, 2H), 
7.51 (s, 2H), 4.57-4.53 (m, 1H), 4.18-4.06 (m, 4H), 3.83-3.78 (m, 1H), 3.57 (t, J = 7.0 
Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.58-2.54 (m, 2H), 2.29-2.22 (m, 2H), 1.98-1.94 (m, 
2H), 1.64-1.59 (m, 2H), 0.82-0.76 (m, 6H); 13C NMR (125 MHz, DMSO-d6) δ 174.0, 
167.8, 161.2, 159.8, 159.7, 144.6, 135.0, 131.6, 130.7, 120.1, 115.1, 55.8, 54.2, 52.5, 
42.5, 38.7, 34.7, 30.6, 28.0, 25.9, 22.8, 17.7, 12.6; MALDI MS calc'd for C23H34N8O6S 
(M+H+) 551, found 551; analytical HPLC purity = 90 %, retention time = 19.1 min (8-
70% B in 30 min). 
 
1H NMR 
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COSY 
 
13C NMR 
 
HPLC 
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N
O HN
C
O
N
O
CONH2
S
CONH2
H2NOC
O2N
2NN  
1H NMR (500 MHz, DMSO-d6) δ 9.00 (d, J = 8.5 Hz, 1H), 8.64 (s, 1H), 8.817 (d, J 
=7.02 Hz, 1H), 7.77 (d, J =7.02 Hz, 1H), 6.96 (s, 4H), 6.52 (s, 2H), 4.63-4.59 (m, 1H), 
4.17-4.04 (s, 8H), 2.86 (t, J = 7.5 Hz, 2H), 2.18-2.05 (m, 2H); 13C NMR (125 MHz, 
DMSO-d6) δ 174.6, 168.7, 164.3, 161.2, 159.5, 159.4, 139.8, 135.4, 130.6, 130.4, 117.4, 
114.7, 64.6, 55.3, 54.8, 52.5, 42.5, 36.4, 28.0; MALDI MS calc'd for C19H23N7O8S 
(M+H+) 510, found 510; analytical HPLC: homogeneous single peak, retention time = 
21.2 min (8-70% B in 30 min). 
 
1H NMR 
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COSY 
 
13C NMR 
 
 
HPLC 
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N
O HN
C
O
N
O
CONH2
S
H2NOC
O2N
2QA  
 
1H NMR (500 MHz, DMSO-d6) δ 9.00 (d, J = 6.5 Hz, 1H), 8.64 (s, 1H), 8.18 (d, J = 7.8 
Hz, 1H), 7.77 (d, J =7.8 Hz, 1H), 6.96 (s, 2H), 6.52 (s, 2H), 4.63-4.57 (m, 1H), 4.08-4.00 
(m, 4H), 3.21 (t, J = 6.5 Hz, 2H), 3.00 (s, m), 2.88 (t, J = 5.5 Hz, 2H), 2.67 (t, J = 6.5 Hz, 
2H), 2.17-2.09 (m, 2H); 13C NMR (125 MHz, DMSO-d6) δ 172.6, 168.8, 163.0, 162.2, 
159.2, 135.5, 131.7, 130.6, 130.1, 127.8, 125.2, 55.7, 54.2, 52.0, 42.8, 37.8, 35.1, 33.8, 
26.8; MALDI MS calc'd for C19H24N6O7S (M+Li+) 487, found 487; analytical HPLC 
purity = 99 %, retention time = 17.0 min (8-70% B in 30 min). 
 
1H NMR 
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COSY 
 
13C NMR 
 
 
HPLC 
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Conformational Analyses 
 
CD.  CD measurements were obtained on an Aviv (model 202 DS) spectrometer.  For 
these experiments the cyclic peptidomimetics were dissolved in H2O with ~1 % NaHCO3: 
MeOH (65:35 v/v) (c = 0.1 mg/ml, 0.1 cm path length).  The CD spectra were recorded at 
25 ˚C. 
 
Molecular Simulations.  CHARMm (Molecular Simulations Inc.) was used for the 
molecular simulations performed in this work.  Explicit atom representations were used 
throughout the study.  The residue topology files (RTF) for all the peptidomimetics were 
built using QUANTA2000 (Molecular Simulations Inc.). 
Molecular Simulation Experiments for 1nk and 2ff.  Quenched molecular dynamics 
simulations were performed using the CHARMm standard parameters.  All molecules 
were modeled as neutral compounds in a dielectric continuum of 45 (simulating DMSO).  
Thus, the starting conformers were minimized using 1000 steps of steepest descent (SD) 
and 3000 steps of the adopted basis Newton-Raphson method (ABNR) respectively.  The 
minimized structures were then subjected to heating, equilibration, and dynamics 
simulation.  Throughout, the equations of motions were integrated using the Verlet 
algorithm with a time step 1 fs, and SHAKE was used to constrain all bond lengths 
containing polar hydrogens.  Each peptidomimetic was heated to 1000 K over 10 ps and 
equilibrated for another 10 ps at 1000 K, then molecular dynamics runs were performed 
for a total time of 600 ps with trajectories saved every 1 ps.  The resulting 600 structures 
were thoroughly minimized using 1000 steps of SD followed by ABNR until an RMS 
energy derivative of ≤ 0.001 kcal mol-1 Å-1 was obtained.  Structures with energies less 
than 3.50 kcal mol-1 relative to the global minimum were selected for further analysis.  
The QUANTA2000 package was again used to display and to classify the selected 
structures into conformational groups.  The best clustering was obtained using a grouping 
method based on calculation of RMS deviation of atom subsets; in this study these were 
the ring backbone atoms.  Thus, threshold cutoff values 0.72 Å were selected to obtain 
families with reasonable homogeneity.  The lowest energy from each family was 
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considered as a typical representative of the family as a whole.  Defined distances were 
measured and compared to distances of various β-turn types. 
 
Table A2. QMD Data for Compound 1NK.  
N
O HN
C
O
N
O
S
CONH2
O
H2N
NH2
 
1NK 
 
Residue family 1 family 2 family 3 family 4 
 lowest energy 
conformer 
lowest energy 
conformer 
lowest energy 
conformer 
lowest energy 
conformer 
     
number in 
family 
183 108 48 22 
lowest energy 
conformer 
(kcal/mol) 
0.00 0.05 2.31 3.73 
distance (Å) 
i+1– i+2* 
5.34 5.35 5.38 5.27 
distance (Å) 
Oi-NHi+3 
4.78 4.79 4.34 3.50 
 
* i+1- i+2 is measured from β-carbons of the side chains. 
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Figure A1. Backbone Conformation of the Lowest Energy Structures for Compound 
1NK 
C O N HS  
family 1 family 2 
 
 
family 3      family 4 
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Table A2. QMD Data for Compound 2FF 
N
O
HN
CO
N
O
CONH2
S
O2N  
2FF 
 
Residue family 1 family 2 family 3 
 lowest energy 
conformer 
lowest energy 
conformer 
lowest energy 
conformer 
    
number in 
family 
120 63 37 
lowest energy 
conformer 
(kcal/mol) 
0.00 1.25 4.79 
distance (Å) 
i+1 – i+2* 
5.36 4.79 4.85 
distance (Å) 
Oi-NHi+3 
2.05 4.22 5.98 
 
* i+1- i+2 is measured from β-carbons of the side chains. 
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Figure A2. Backbone Conformation of the Lowest Energy Structure for Compound 2FF 
C O N HS  
 family 1      family 2 
                    
 family 3 
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Temperature Coefficient 1H NMR Experiment (500 MHz, DMSO-d6): 
Temperature coefficients of amide protons were measured via several 1D experiments in 
the range of 25-55 oC adjusted in 5 oC increments with an equilibration time of 
approximately 30 min after successive temperature steps. 
 
Figure A3. Temperature Coefficient for 1NK. 
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Figure A4. Temperature Coefficient for 2FF. 
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